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Resumo 
 
Bronquiectasia é uma doença pulmonar obstrutiva resultante da inflamação crónica 
dos brônquios. Pseudomonas aeruginosa associa-se a uma diminuição da função 
pulmonar em bronquiectasia e agudizações mais frequentes. Esta bactéria é 
frequentemente subdiagnosticada, o que pode limitar o tratamento dos doentes. 
Atualmente, a terapia baseada em antibióticos é essencialmente dirigida a uma única 
estirpe bacteriana, no entanto os doentes com bronquiectasia podem estar infetados 
por múltiplas estirpes de P. aeruginosa. Assim, o diagnóstico e implementação 
imediata de uma terapia dirigida podem melhorar o prognóstico e limitar danos em 
órgãos dos doentes.  
O principal objetivo do presente trabalho foi caracterizar a evolução e estrutura da 
população de P. aeruginosa em doentes com diferentes tipos de bronquiectasias, 
alguns deles também diagnosticados com fibrose cística (FC), utilizando o método 
SNaPaer. Assim, começamos por o otimizar o método para aplicação direta em 
colónias de P. aeruginosa, selecionando o melhor pré-tratamento para a amplificação 
dos genes alvo. Dos vários tratamentos, a pré-incubação com Proteinase K provou ser 
a mais eficiente, com 96% de resultados positivos. Em seguida, testou-se a 
capacidade do SNaPaer para identificação e genotipagem de mais de 200 isolados 
bacterianos obtidos em meio de cultura Cetramida a partir de amostras clínicas de 
doentes com bronquiectasias. Nestes isolados identificaram-se 43 perfis SNaP 
diferentes. A partir dos 43 perfis, 38 foram exclusivos de doentes portugueses, não 
tendo sido descritos anteriormente no banco de dados pubMLST 
(http://pubmlst.org/paeruginosa/). Os perfis obtidos revelaram-se altamente específicos 
(> 90%) para as populações de doentes, mesmo dentro dos grupos de doentes 
considerados (doentes com e sem FC). A microevolução foi o mecanismo de evolução 
mais comum em estirpes de P. aeruginosa de doentes com bronquiectasias. Contudo, 
alguns doentes parecem ser colonizados simultaneamente por múltiplas estirpes, 
particularmente doentes FC com bronquiectasias. Os doentes submetidos a terapias 
antibacterianas mais agressivas apresentaram, no final da terapia, perfis SNaP muito 
distintos relativamente ao perfil SNaP do primeiro isolado. 
O presente estudo contribui para aprofundar a caracterização da diversidade genética 
em doentes com bronquiectasias, abrindo novas portas para alcançar um melhor 
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conhecimento sobre os fatores subjacentes aos padrões de evolução e diversidade em 
populações de P. aeruginosa. 
 
Palavras-chave: espécies de Pseudomonas, estrutura da população, 
minisequenciação, diversidade genética, bronquiectasias, SNaPaer. 
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Abstract 
 
Bronchiectasis is an obstructive pulmonary disease resulting from chronic bronchial 
inflammation. Pseudomonas aeruginosa has been associated with decreased lung 
function in bronchiectasis and frequent exacerbations. However, this bacterium is 
frequently under-diagnosed, which may limit the treatment of the patients. Furthermore, 
antibiotic therapy is primarily directed to single bacterial strains, while patients with 
bronchiectasis may be colonised or infected by multiple P. aeruginosa strains. Thus, 
prompt diagnosis and immediate implementation of a targeted therapy can improve the 
prognosis and restrict extensive damage into patient organs.  
The main goal of the present work was to characterise the evolution and population 
structure of P. aeruginosa from different bronchiectasis patients, some of them also 
diagnosed with cystic fibrosis (CF), using the SNaPaer assay. Therefore, we first 
optimised the method for direct application on P. aeruginosa colonies by selecting the 
optimal pre-treatment for posterior gene amplification. Afterwards, we tested the ability 
of SNaPaer for identification and genotyping in more than 200 P. aeruginosa isolates 
collected from bronchiectasis patients.  
From the tested pre-treatments, proteinase K was the most efficient method with 96% 
of positive results. Based on reproducibility, cost and practical applicability at the 
laboratorial routine, the pre-treatment with Proteinase K was the selected method for 
posterior genotyping analysis. The SNaPaer assay proved to be good and reliable for 
identification and genotyping P. aeruginosa. In 207 clinical isolates, a set of 43 different 
SNaP profiles were identified. A group of 38 out of 43 SNaP profiles were exclusive 
detected in Portuguese patients and had not been previously described at pubMLST 
database (http://pubmlst.org/paeruginosa/). SNaP profiles were highly specific (>90%) 
for the patient population, even considering the patient groups (CF and non-CF 
patients). Microevolution events were the most common mechanism of evolution in P. 
aeruginosa strains from bronchiectasis patients. However, some patients seem to be 
colonised simultaneously with multiple strains, particularly CF patients with 
bronchiectasis. Patients submitted to aggressive antibiotic therapies presented at 
the end of the therapy P. aeruginosa with SNaP profiles very distinct from the SNaP 
profile of first isolate. 
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The present study has contributed to the characterisation of genetic diversity of P. 
aeruginosa in bronchiectasis patients, opening new perspectives to understand the 
factors underlying the patterns of evolution and diversity in P. aeruginosa clinical 
populations. 
  
Key-words: Pseudomonas species, population structure, minisequencing, genetic 
diversity, bronchiectasis, SNaPaer.  
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1. Introduction 
 
1.1 Bronchiectasis 
Bronchiectasis is a common long-term respiratory condition characterised by an 
anomalous, chronic enlargement of the bronchi. The prevalence of this lung 
disorder is highly variable, ranging from four per 100,000 habitants in New Zealand 
to 1,600 per 100,000 in Alaskan Eskimo population for non-cystic fibrosis (CF) 
bronchiectasis (Goeminne and Dupont, 2010). In people with certain diseases, 
bronchiectasis can be common as it is the case of CF patients, with more than half 
of the patients presenting this condition (Vonberg et al., 2005). Individuals with 
bronchiectasis have a history of chronic and recurrent airway infections, mainly 
caused by Pseudomonas aeruginosa bacteria. Depending on the underlying origin, 
those infections may implicate the whole respiratory tract, causing sinus and lung 
illness. 
Since the first description by René Laënnec in 1819 (Roguin, 2006), the 
bronchiectasis has suffered substantial changes in respect to its incidence, 
aetiology, manifestation, and treatment. Antibiotics have significantly improved the 
quality of life of patients with bronchiectasis. Those drugs have transformed post-
infectious bronchiectasis in an uncommon respiratory condition in some developed 
countries.  
Later in 1989, with the discovery of the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene, there was an increase in the number of studies related to 
the biology of the airway cells, as well as the mechanisms linked to the transport of 
water and salts into the mucus (Marcet and Boeynaems, 2006; Boucher, 2007; 
Kreda et al., 2012). This knowledge allowed considerable improvements in the 
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treatment of CF bronchiectasis. However, the treatment of non-CF bronchiectasis 
is not necessarily the same as for CF bronchiectasis and therefore, improvements 
in the quality of life in both groups are still required.  
Recently, few studies have proved that bronchiectasis remains a notorious problem 
in developing countries, particularly in people over 75 year old (Seitz et al., 2010). 
Thus, it is essential to understand the elementary mechanisms of the disease, the 
microorganisms involved and how the lung damage is perpetuated. 
 
1.1.1. Pathophysiology, diagnosis and treatment of bronchiectasis  
Bronchiectasis is the anatomic alteration of the conducting airways, in which part of 
bronchial tree is abnormally stretched and widened (Kim and Kim, 2012). In these 
circumstances, extra mucus tends to be produced and settle in the enlarged 
airways (Figure 1). Accompanying the enlargement of the bronchi, the cilia present 
in the airways are also damaged and their ability to clear secretions decreases 
considerably. Failure to clean mucosal secretions allows the accumulation of 
microorganisms and particles in the patient lungs that lead to increased secretion 
and inflammation, which further damage the airways.  
Bronchiectasis may be classified as localised or diffused. Localised bronchiectasis 
is characterised by the damage in a single portion of the lung (King, 2009). When 
the damage extends and occurs all throughout the lungs it is called diffuse 
bronchiectasis. Localised bronchiectasis is generally associated with necrotising 
pneumonia, obstructive lesion and tuberculosis. On the other hand, diffuse 
bronchiectasis is usually related with CF, immobile cilia syndrome, 
immunodeficiencies, hypogammaglobulinemia and childhood infections.  
Bronchiectasis patients with a stable status have high levels of inflammatory 
markers, such as C-reactive protein and erythrocyte sedimentation rate (Brody et 
al., 2006), and these markers usually increase during exacerbations (Smith et al., 
1996). The levels of these markers are significantly different before and after the 
treatment with antibiotics. Severe cases of bronchiectasis are characterised by 
chronic cough, dyspnoea and sputum production, which can be interposed by punctual 
episodes of acute exacerbation. The definition of acute exacerbation is still under 
discussion. However, a bronchiectasis patient is reported to have an acute 
exacerbation if some of the following indicators are present with no other explanation: 
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increased cough, change in sputum production, increased dyspnoea, fever over 38°C, 
increased wheezing, fatigue, decreased exercise tolerance, lethargy, malaise, reduced 
pulmonary function (PF), changes in chest sounds or radiographic changes consistent 
with a new infectious process (O'Donnell, 2008; Goeminne and Dupont, 2010).  
The diagnosis of this lung condition is usually performed by high-resolution chest 
computed tomography (HRCT) (O'Donnell, 2008). The test generates detailed 
images of the airways, lungs and other structures, which help to determine the 
location and extent of airway damage. Other complementary tests could be applied 
to facilitate the diagnosis of this disease such as blood tests, sputum culture, lung 
function tests, sweat test and bronchoscopy. Nevertheless, HRCT remains the 
more accurate test for bronchiectasis diagnosis.  
Nowadays, the treatment of bronchiectasis includes controlling infections, inflamatory 
process and bronchial secretions by clearing airway obstructions. The control of 
bronchial secretions includes the continued usage of mucoactives and anti-
inflammatory agents; antibiotics are used to prevent and treat damaging infections 
(Evans et al., 2007). In a small number of cases, surgery is suggested to treat localised 
bronchiectasis, removing affected bronchial portions that could cause progression of 
bronchiectasis (Yoon et al., 2002; Ötgün et al., 2004). Lastly, the lung transplantation 
can be considered in some severe cases. 
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Figure 1. Components of mucociliary clearance mechanism. The mucus is secreted from sub-mucosal glands and 
goblet cells. Mucociliary clearance is the primary mechanism of clearance of mucus. A: In a normal mucociliary 
clearance situation, the cilia beat in a coordinated way in the periciliary fluid layer propelling the mucus towards the 
mouth. B: In an abnormal mucociliary clearance situation, mucus accumulates and cough becomes the secondary 
mechanism for clearance of mucus. 
 
1.1.2. Clinical pathologies related to bronchiectasis  
The improvements in bronchiectasis diagnosis support the assumption that a high 
percentage of chronic respiratory morbidity can be caused by this disorder (Patel 
et al., 2004; King et al., 2006). Nevertheless, bronchiectasis remains 
underdiagnosed in several clinical units or coexists with other disorders (such as 
infections, connective tissue diseases and immunodeficiencies). The reported 
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prevalence of bronchiectasis is probably underestimated (Barker, 2002; Revel et 
al., 2002; Patel et al., 2004; King et al., 2006).  
The aetiology of bronchiectasis may vary, being associated with a range of 
conditions some of them related with genetic disorders and others with life 
acquired illnesses (Nicotra et al., 1995; Pasteur et al., 2000; Kelly et al., 2003; 
Pasteur et al., 2010). The cause of bronchiectasis may be very difficult to ascertain 
and it is more correct to consider several conditions associated with the 
development or a risk factor for the pathology.  The list of associated diseases is 
large; some of the most common diseases associated with bronchiectasis are 
described below.  
 
1.1.2.1. Infections 
On the top of the list of risk conditions associated with bronchiectasis is the clinic 
history of severe infection (33–42%) (Chalmers and Hill, 2013). A wide range of 
necrotising infections that are either ineffectively treated or not treated at all may 
be enough to the emergence of bronchiectasis (Loebinger et al., 2009; Chalmers et 
al., 2012). Klebsiella species, Staphylococcus aureus, Mycobacterium tuberculosis, 
nontuberculous mycobacteria, Mycoplasma pneumoniae, Measles virus, Pertussis 
virus, Influenzae virus, herpes simplex virus and several types of adenovirus are some 
of the organisms that have been known to cause bronchiectasis. When a patient 
develops bronchiectasis many other organisms colonise the injured bronchi and may 
cause permanent damage and periodical cases of exacerbations. Haemophilus 
species and Pseudomonas species are the organisms that most commonly comprise 
the injured lungs (Angrill et al., 2002; King et al., 2007).  
 
1.1.2.2. Connective tissue diseases 
Connective tissue diseases, such as rheumatoid arthritis, systemic sclerosis, 
ankylosing spondylitis and systemic lupus erythematous may also be in the origin 
of bronchiectasis (Kozuka et al., 2001). These autoimmune disorders represent 3–
6% of the bronchiectasis cases (Chalmers and Hill, 2013). Connective tissue 
diseases are characterised by an abnormal function of the immune system, which 
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attacks healthy tissue triggering inflammation. In a few number of cases the 
inflammation can spread to the lungs, causing the symptoms of bronchiectasis. 
 
1.1.2.3. Allergic bronchopulmonary aspergillosis  
Allergic bronchopulmonary aspergillosis (ABPA) is a respiratory disease 
characterised by a hypersensitivity response of the immune system to inhaled 
Aspergillus antigen (most commonly Aspergillus fumigatus antigen) (Roxo et al., 
2013). ABPA causes airway inflammation which may eventually develop into 
bronchiectasis (it represents 1–7% of the total number of bronchiectasis) that is 
most marked in the central portions of the airways (Chalmers and Hill, 2013). 
Recurrent acute episodes that are untreated or not treated efficiently may result in 
progressive pulmonary fibrosis that is frequently seen in the upper portion of the 
airways. Patients with ABPA usually have a long history of poorly controlled 
asthma, cough, shortness of breath, chronic sputum production, coughing up 
brownish mucoid plugs or haemoptysis, and exercise intolerance. 
 
1.1.2.4. Immunodeficiency 
Another condition that may be a cause of bronchiectasis (1–8% of the total number 
of cases) is immunodeficiency caused by the absence or defects in certain immune 
cells (Truong, 2013; Chalmers and Hill, 2013). Individuals with immunodeficiency 
disorders have recurrent infections that are more severe and that last longer than 
usual. The immunodeficiency may be congenital or acquired, as it is the case of 
patients with Human immunodeficiency virus (HIV).  
 
1.1.2.5. Recurrent aspiration or inhaled foreign body 
Foreign body aspiration occurs when stomachal or oral chewed materials reach the 
lungs (Adegboye et al., 2003). The aspiration may occur from oropharyngeal 
dysphagia, a reduced ability to gulp, which may cause saliva or food to enter the 
lung. Another possible cause of aspiration is gastroesophageal reflux disease, 
which is characterised for a dysfunction in the smooth muscle valve between the 
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oesophagus and the stomach. The valve allows stomachal contents to flow back 
up into the oesophagus and subsequently into the lungs. If the aspiration is 
frequent or severe, it may lead to inflammation of the airways and cause 
bronchiectasis (2–4%) (Chalmers and Hill, 2013).  
 
1.1.2.6. Cystic fibrosis 
One of the most studied diseases within the list of underlying causes of bronchiectasis 
is CF, justifying the occurrence of 2–4% of the total group of bronchiectasis in the 
patients (Chalmers and Hill, 2013). CF, also known as mucoviscidosis, is a recessive 
genetic disease that occurs in all human populations but it is more common among 
Caucasians (Davis et al., 1996). CF causes several complications in various organs, 
including chronic pulmonary infections, rhinosinusitis, nasosinusal polyposis, bad 
gastrointestinal absorption ensuing from pancreatic dysfunction, spastic ileus of the 
newborn, retal prolapsed and infertility due to obstruction of the deferent ducts (Nick 
and Rodman, 2005). This inherited disease is characterised by an anomalous function 
of cAMP-regulated chloride ion channel of the airway epithelial cells, which is caused 
by a mutation on the CFTR gene located in long arm of chromosome 7. The reduction 
of the functionality of CFTR, as an effect of these mutations, causes a hyperabsorption 
of sodium chloride and therefore, a decrease in salt and water in the respiratory 
epithelium. Thus, there is an increase of mucus viscosities, which impedes the efficient 
clearance of the sputum, allowing the bronchial obstruction and enlarging bacterial 
colonisation and subsequent infection (Norez et al., 2009).  
 
1.1.2.7. Primary ciliary dyskinesia 
Primary ciliary dyskinesia is a genetic disease that causes a defect in the action of 
the cilia lining the respiratory tract, the fallopian tube and also of the flagella of 
sperm in males (Noone et al., 2004). The inappropriate sweeping of cilia may lead 
to a poor mucociliary clearance, frequent pulmonary infections and, ultimately, 
bronchiectasis. The evolution of the disease is variable and lung transplantation is 
required in severe cases. An early diagnosis may significantly reduce the 
infections, leading to a better prognosis in patients. Early treatment based on chest 
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physiotherapy techniques may reduce the occurrence of lung infection and slow 
down the progression of bronchiectasis (1–2%) (Chalmers and Hill, 2013). 
 
1.1.2.8. Inflammatory bowel disease 
Inflammatory bowel disease may occasionally be a cause of bronchiectasis in 1–
2% of the cases (Chalmers and Hill, 2013; Desai et al., 2011). This disease 
comprises a variety of inflammatory conditions of the colon and small intestine. 
The main types of inflammatory bowel disease are Crohn's disease and ulcerative 
colitis. This disease causes inflammation and narrowing of the airways, which may 
involve specific or diffuse areas. Pronounced inflammation can sometimes cause 
marked airway obstruction. These conditions may be amenable by treatment with 
inhaled and oral corticosteroids.  
 
1.1.2.9. Congenital airway structural abnormality 
Bronchiectasis may also be a result of several abnormal bronchoalveolar 
developments, including bronchopulmonary sequestration, Mounier-Kuhn 
syndrome and Williams-Campbell syndrome (Pappas et al., 2011). These 
pathologies are associated with bronchiectasis in 1–2% of the cases (Chalmers 
and Hill, 2013). Congenital airway structural abnormality results in chronic 
respiratory tract infections and dilatation of the airways which lead to 
bronchiectasis. Mounier-Kuhn syndrome is characterised by dilation of the trachea 
and segmental bronchi, which lead to repeated chest infections and 
bronchiectasis. Williams-Campbell syndrome is a disease of the airways where 
cartilage from lobar to first- and second-generation segmental airways is defective, 
resulting in extensive peripheral bronchiectasis.  
 
1.1.2.10. Idiopathic bronchiectasis 
Even with thorough clinical, pathologic and laboratory analysing, 30 to 53% of 
related cases of bronchiectasis have an idiopathic cause (Chalmers and Hill, 
2013). However, the compartmentalisation of this group in specific conditions and 
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their understanding are far from being completely scrutinised. Therefore, in recent 
years, there has been an increase of microbiology studies of the lungs of non-CF 
bronchiectasis patients (Kapur et al., 2012; Tunney et al., 2013). 
 
1.2. Microbiology of the lungs of bronchiectasis patients 
A wide range of pathogens have been isolated from the lungs of bronchiectasis 
patients. In these patients, Haemophilus influenzae is the most common pathogen 
(range 29%–70%) followed by Pseudomonas aeruginosa (range 12%–33%) (Angrill et 
al., 2002; King et al., 2007). Chemical mediators released by H. influenzae and P. 
aeruginosa may also directly affect cilia function, reviling the ciliated epithelium 
and inhibiting the transport of mucus (Wilson et al., 1988). Bacterial pathogens 
release various proteins, including glycoproteins, which attract neutrophils. H. 
influenzae is able to cause direct injury in the airway epithelium by invasion of the 
bronchial wall and interstice of the lung (Möller et al., 1998).  
P. aeruginosa has also high impact on the respiratory tract. It can form biofilms 
(Davies and Marques, 2009; Davies and Bilton, 2009) which occur primarily in the 
progressive disease and produce an impenetrable matrix (containing proteins and 
sugars) around the bacteria. This protects P. aeruginosa from the aggressively 
immune system and antibiotics, allowing the bacterial infection to cause severe 
damage to the underlying lung. As lung function decays, P. aeruginosa is the most 
commonly isolated pathogen in patients with the worst prognosis. Other 
microorganisms such as Streptococcus pneumonia, Moraxella catarrhalis, Burkholderia 
cepacia complex species and Staphylococcus aureus may be found in bronchiectasis 
patients.  
S. pneumoniae is a Gram-positive bacterium which may cause otitis media, sinusitis or 
lower airway infections in bronchiectasis patients. Although this organism is rare in CF 
patients, in non-CF bronchiectasis patients it can be found in more than 37% of the 
cases. S. pneumoniae can use a wide range of molecules to adhere to airway cells and 
releases an Immunoglobulin A (IgA) protease and pneumolysin (a toxin) which may 
lead to invasion, inflammation and tissue injury (Kadioglu et al., 2008).  
Another organism which is commonly found in the upper respiratory tract of these 
patients is M. catarrhalis. As previously described for S. pneumoniae, M. catarrhalis 
may cause otitis media or sinusitis. This bacterium is isolated in more than 27% of 
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chronic obstructive pulmonary disease (COPD) bronchiectasis patients; in other 
patients with bronchiectasis the frequency of isolation can be lower (Verduin et al., 
2002). The first acquisition of M. catarrhalis does not cause bronchiectasis 
exacerbation. A longitudinal study of 50 patients with COPD suggested an association 
between second colonisation by M. catarrhalis and exacerbation cases (Murphy et al., 
2005).  
Burkholderia species and S. aureus are more rarely found in patients with 
bronchiectasis. Burkholderia cepacia complex species are Gram-negative rod-shaped 
bacteria with a prevalence of 3% in CF patients that have been associated with a high 
risk of developing fatal cepacia syndrome (Mahenthiralingam et al., 2005; Vanlaere et 
al., 2009). However, few cases are known in non-CF patients due to the small number 
of studies in these patients (Ledson et al., 1998). S. aureus is rarely related with airway 
infection, but may cause very aggressive post-influenzae infections. It is usually related 
with early infection in CF bronchiectasis, being less common in non-CF bronchiectasis 
(Pasteur et al., 2000). However, in non-CF bronchiectasis there is an association 
between S. aureus and ABPA (Shah et al., 1999).  
Despite the huge diversity of microorganisms that can be present in bronchiectasis, P. 
aeruginosa remains the major focus of the scientific community when studying this 
disorder. 
 
1.3. Pseudomonas aeruginosa 
P. aeruginosa is a versatile bacterium, extensively recognised to cause serious 
infections on patients with CF and non-CF bronchiectasis. These bacteria are 
frequently found in association with animals and plants, as well as in distinct 
environmental samples (air, water or soil). This wide distribution implies a high genomic 
plasticity and the presence of several adaptation mechanisms. P. aeruginosa is not 
demanding in its nutritional requisites: it grows in minimal culture medium with simple 
molecules or even in deprived culture conditions (Higashi, 1960; Favero et al., 1971; 
Schreiber et al., 2007). This Gram-negative bacterium may produce various types of 
soluble pigments including pyoverdin (yellow-green and fluorescent), pyorubin 
(red-brown) and pyocyanin (blue-green). Pyoverdin is generously produced in low-
iron medium content, pyorubin is also believed to be produced when the organism 
is under oxidative stress, while the latter is associated with suppurative infections 
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(Pollack, 2000). P. aeruginosa may grow in a broad range of environments 
including at extreme temperatures, although the optimal growth is observed at 37 
ºC. Additionally, these bacteria present a very hierarchical quorum sensing which 
coordinates the formation of biofilms, swarming motility, exopolysaccharide 
production and cell aggregation (Rumbaugh et al., 2000). Indeed, the high genomic 
plasticity, the presence of several adaptation mechanisms, the ability to digest a wide 
range of components and the quorum sensing are some characteristics that allow the 
hostility of P. aeruginosa in bronchiectasis patients. 
 
1.3.1. Pseudomonas aeruginosa acquisition in bronchiectasis 
patients 
The acquisition of P. aeruginosa strains by patients can be done by several routes, 
due to the ubiquitous nature of this bacterium. Individuals may contact with the 
microorganism from different sources and even their homes may represent a 
reservoir for the bacteria. An interesting study on healthy individuals showed that 
more than one third of this population may carry P. aeruginosa in their airways 
during occasional acute viral respiratory infections (Johansen and Høiby, 1992). 
Healthy individuals fight the organism spontaneously, while patients with 
bronchiectasis cannot eliminate the bacterial colonisation. Therefore, non-
bronchiectasis individuals with flu may be a source of viral and P. aeruginosa 
infections for those with bronchiectasis (van Ewijk et al., 2006). Hospital 
environment has been carefully monitored regarding the presence of P. 
aeruginosa. In what concerns patient cross-transmission, this occurrence has been 
accepted as uncommon (Govan and Deretic, 1996; Govan, 2000; Schmid et al., 
2008); a similar strain of P. aeruginosa was only described in patients with close 
contact (Kelly et al., 1982; Grothues et al., 1988). A study on a hospital kitchen 
also showed the presence of P. aeruginosa in 82% of tomatoes and 27% of tomato 
salads, the food representing sometimes a risk for patients admitted at hospitals 
(Shooter et al., 1971; Kominos et al., 1973). In the case of drinking water, there are 
reports of contamination with P. aeruginosa in large dispensers (Baumgartner and 
Grand, 2006) as well as in commercial bottled water (Wilkinson and Kerr, 1998). P. 
aeruginosa is often found in intensive care units, particularly in washbasins, sinks 
and on the hands of the medical staff (Döring et al., 1991; Döring et al., 1993; 
Dwivedi et al., 2009). However, in intensive care units where precautions are taken 
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to avoid P. aeruginosa cross-infection (such as using gloves and disinfectants to 
clean material when moving between patients), there was no evidence that hospital 
environment was an important source of infection (Zembrzuska-Sadkowska et al., 
1995). A study that investigated the frequency of contamination with P. aeruginosa 
at different sites of households of CF patients, collecting samples from bathroom, 
kitchen and toilet, detected P. aeruginosa strains in 72% of the samples; the 
highest percentage was reported on shower drains (Regnath et al., 2004). P. 
aeruginosa has been also detected on domestic dogs and cats that by contact may 
contribute to spread these bacteria among people more susceptible to 
bronchiectasis (Buma et al., 2006; Cole et al., 2006; Tolar et al., 2006). This 
bacterium is found in many aquatic environments, especially warm milieus containing 
organic material or material contaminated by human or animal waste (Botzenhart and 
Döring, 1993). Even though P. aeruginosa is not considered a marine organism, due to 
the high salt concentrations that inhibit its growth, there is some evidence suggesting 
that the P. aeruginosa can survive in seawater (Vasconcelos and Swartz, 1976). 
Swimming pools are often contaminated with the opportunistic pathogen P. aeruginosa. 
In 2007, the 50-metre pool at Cook and Phillip Park was closed in the City of Sydney 
due to the persistence of P. aeruginosa contamination (Rice et al., 2012). A definite 
hazard for bronchiectasis patients are hydrotherapy pools, jacuzzis and hot tubs. Hot 
tub folliculitis, green nail syndrome, infective endocarditis, invasive external ear 
infections and puncture wound osteomyelitis are some of the acquired infections 
reported from these sources (Gregory and Schaffner, 1987). Nevertheless, these 
places are usually safe when the recommended programmes of maintenance 
(monitoring of pH and total dissolved solids, addition of liquid chlorine, etc.) are carried 
out. Soil may also be a reservoir for P. aeruginosa; it was documented that 24% of 
soil samples from many areas in California contained P. aeruginosa (Green et al., 
1974).  
 
1.3.2. Pseudomonas aeruginosa colonisation in bronchiectasis 
patients 
After lung invasion, P. aeruginosa must adhere to the host in order to establish a 
successful colonisation and resist the onslaughts of the immune system. In 
patients with stable bronchiectasis the airways are colonised by this bacterium in 
5-31% of the cases (Nicotra et al., 1995; Pasteur et al., 2000; Angrill et al., 2002; 
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King et al., 2007). Once acquired, P. aeruginosa can only be eradicated in the 
early stage of colonisation. 
In healthy lungs, bacteria are partially removed by the mucociliary clearance 
mechanism. This mechanism functions to expel particles or microorganisms 
inhaled into an airway (Robinson and Bye, 2002). Some important characteristics 
for a good mucociliary clearance are the number of cilia, their activity and 
coordinated movement and the volume of airway surface liquid (Robinson and Bye, 
2002; Tarran et al., 2006) (Figure 1 A). The airway surface liquid is composed by 
water, ions and macromolecules produced by surface epithelial cells and/or sub-
mucosal glands (Tarran et al., 2006). In coordination with ciliated epithelium, the 
airway surface liquid conduces the foreign particles toward the pharynx where it is 
finally expectorated from the airways (through coughing and sneezing). In 
bronchiectasis patients this mechanism fails and P. aeruginosa can easily adhere 
to bronchiectasis mucin (Nelson et al., 1990). This adherence cannot be possible 
without the flagellar cap protein FliD (Arora et al., 1998). Other cell components 
help the adherence process to the mucin such as lipopolysaccharides (Pier et al., 
1997), flagellin (Feldman et al., 1998) and pili (Saiman and Prince, 1993). The 
adherence process is important for bacterial colonisation and subsequent infection. 
There are three forms of P. aeruginosa that may colonise the lungs of 
bronchiectasis patients (Norez et al., 2009; Sonnleitner et al., 2009). In a first step, 
rough and smooth forms colonise the lung, which may be eradicated by early 
aggressive antibiotic therapy. When the treatment is not effective, a new form 
colonises the lung, the mucoid form, which may result from the conversion of 
previous colonies or from the acquisition of a new bacteria from environment 
(Vernez et al., 2005). The mucoid P. aeruginosa cannot be easily eradicated by 
antibacterial therapy and can persist continuously in the lungs (Mena et al., 2008). 
Moreover, the immune system of patients appears to overreact to all types of these 
bacteria by chemotactic stimuli (Strieter et al., 1993). This response includes the 
recruitment of macrophages and neutrophils (Figure 2). Activated neutrophils release 
oxygen radicals and proteolytic enzymes to exterminate bacteria, which also injury 
epithelium and protective proteinase inhibitors. The macrophages and airway epithelial 
cells release some substances such as InterLeukin-8 (IL-8) and Tumor Necrosis Factor 
(TNF), which influence cell migration. However, bacteria may not be fully eradicated, 
resulting in chronic inflammation and infection (Mikami et al., 1998; Stockley, 1998). As 
consequence of bacterial presence, the tissue is damaged and eventually the 
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bacteria can destroy a part of the lung. A mucoid type of P. aeruginosa is indicative 
of the overproduction of alginate, a capsule-like polysaccharide. This capsule is a 
barrier to phagocytosis, a mechanism for bacterial adherence that neutralises 
oxygen radicals, which make this polysaccharide an important virulence factor 
encountered primarily in CF (Bragonzi et al., 2005; Hassett et al., 2009).  
 
 
Figure 2. Involvement of innate and adaptive immunity in bronchiectasis.  Chemotactic bacterial stimuli 
activate both macrophages (M0) and airway epithelial cells, which in turn produce InterLeukin 8 (IL-8), Necrosis 
Factor-α (TNF-α) and InterLeukin 1 (IL-1). These primary pro-inflammatory mediators are responsible for 
neutrophil activation and recruitment into the airways. Finally, InterLeukin 10 (IL-10) and InterLeukin 12 (IL-12) 
secreted by activated M0 favour the development of T helper 1 (Th1) or a T helper 2 (Th2) responses. IC - 
Immune Complexes; IFN- γ - Interferon-γ; IgG - Immunoglobulin G; IL-4 - InterLeukin 4; M1 - Activated 
macrophages. Adapted from Conese et al., 2003.  
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1.4. Genomic diversity of Pseudomonas aeruginosa 
The colonisation of bronchiectasis patients and phenotypic exchange of P. 
aeruginosa on this environment would not be possible without a very plastic 
genome. The P. aeruginosa genome consists of a single circular chromosome 
composed of a conserved core genome and a changeable flexible genome (Figure 3). 
At present, there are 12 complete genomes accessible in online databases 
(National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/), 
Pseudomonas Genome Database (http://www.pseudomonas.com/) and Ensembl 
(http://www.ensembl.org/index.html). The size of the various P. aeruginosa 
genomes is variable, ranging from 6 Mb to 7 Mb (Schmidt et al., 1996; Stover et al., 
2000). This fluctuation is responsible for the genetic diversity that arises and is 
preserved through interchange between genetic and ecological factors (Spiers et al., 
2000). The essential genes, which are indispensable to support cellular life, are 
normally more conserved than nonessential (Dotsch et al., 2010). At the core genome 
where housekeeping genes are found studies by Kiewirtz and Tümmler revealed an 
average rate of sequence polymorphism of 0.3% (Kiewitz and Tummler, 2000). The 
same authors reported less than 0.5% of substitution rates in a restricted group of 
conserved genes in the P. aeruginosa genome. Genes involved in flagellar 
biosynthesis and genes whose products are involved in the biosynthesis of the 
siderophore pyoverdine and the receptor for ferripyoverdines were the highest 
polymorphic genes at the core genome (Tsuda et al., 1995; Lehoux et al., 2000).  
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Figure 3. Pseudomonas aeruginosa genomes comparison. The gold circle represents the core genome, the 
second circle shows the functional annotations. The remaining circles indicates  the accessory genes from PA14 
(blue) PA2192 (green), C3719 (purple), PAO1 (red), and PACS2 (teal). Adapted from Mathee et al., 2008. 
 
In contrast, the flexible genome includes genes that are found in more particular 
populations of P. aeruginosa. These fragments are clustered in certain loci and not 
dispersed randomly throughout the core genome. These loci are located in many 
regions of genomic plasticity which are usually called genomic islands (>10 kb) or islets 
(<10 kb) (Mathee et al., 2008). The genes of the accessory genome may encode 
proteins and RNAs that contribute to the adaptation of bacteria to specific niches (Kung 
et al., 2010). Additionally, plasmids constitute an important part of the P. aeruginosa 
gene pool, particularly the multidrug-resistant plasmids (Shahid et al., 2003).    
Genomic diversity of P. aeruginosa may be a consequence of various molecular 
events, including deletions, insertions, inversions and point mutations. The 
genomic variation of the strain PAO1 has been repeatedly reported during in vitro 
sub-culturing. The strain PAO1 sequenced by Stover (2000) presented an inversion 
of 25% of the genome relative to DSM-1707, another PAO1-derived isolate previously 
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mapped by Schmidt (1996 and 1998). Both strains are clonally derived from the same 
ancestor (Holloway et al., 1994), and such differences arised during the sub-culturing 
processes. The strain PAO1 differs from the original PAO by 1.7 Mbp inversion 
between rrnA and rrnB loci, which are orientated in opposite directions, and a deletion 
of approximately 20 kbp near to rrnC locus. These events do not appear to be isolated; 
PAO1 stocks from other laboratories have the same inversion. It was also found that 
two different stocks present a defective LasR function due to point mutations in the 
lasR genes (Heurlier et al., 2005). 
Chronic colonisation of P. aeruginosa in the respiratory tract of bronchiectasis 
patients is characterised by genome mosaicism (presence of genomic islands 
obtained through horizontal transfer of genes), however, it is not reflected by 
readily visible phenotypes (Ernst et al., 2003). Comparison among complete 
genomes (Spencer et al., 2003) has revealed that some of the gene islands 
present high number of single nucleotide polymorphisms (SNPs). Large deletion 
events (of more than 100 kbp) are also found when compared two different P. 
aeruginosa isolates obtained during bacterial evolution process in the 
bronchiectasis lung (Ernst et al., 2003). In addition, the human airways do not only 
predispose to extreme changes of DNA framework but also to possible 
recombination  events in single genes (Pirnay et al., 2002). Strains with high levels 
of mutation rates possibly drive the acquisition and fixation of mutations in P. 
aeruginosa populations of bronchiectasis patients (Oliver et al., 2000; Maciá et al., 
2005). Using these genetic mechanisms, P. aeruginosa may easily adapt to fit and 
survive in the different environments. One example of genome flexibility is the 
acquisition of a large cluster of genes involved in diterpenoid metabolism by the 
PA2192 strain that allow the adaptation to environments rich in abietane 
diterpenoid resins (Mathee et al., 2008); this strain later colonised and infected a 
CF patient in the United States. Thus, the acquisition of new genetic elements 
appears to be conditioned by nutritionally limitations of P. aeruginosa strains. 
Correct identification and characterisation of P. aeruginosa may possibly improve 
the selection of appropriate therapy and prevent the development of multidrug-resistant 
bacteria.  
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1.5. Identification of Pseudomonas aeruginosa 
Correct diagnosis and treatment of P. aeruginosa is severely hampered by the 
absence of a reliable identiﬁcation system. A wide range of methods are described for 
P. aeruginosa identification, including conventional methods (e.g. morphology and 
biochemical tests), indirect molecular strategies (e.g. MALDI-TOF MS system) and 
direct molecular strategies involving PCR and sequencing analysis. However, here we 
will focus our attention in conventional and direct molecular strategies for identification. 
 
1.5.1. Conventional identification 
Culture selective media have been long used for identification of various bacteria 
including P. aeruginosa. A basic medium, containing components such as magnesium 
chloride, potassium sulphate, protein hydrolysate and agar, is enough for the 
identification. Some examples are Cetrimide, phenanthroline and 9-chloro-9-[4-
(diethylamino)phenyl]-9,10-dihydro-10-phenylacridine hydrochloride and chromogenic 
media (Brown and Lowbury, 1965; Fujita et al., 1992; Laine et al., 2009). Nevertheless, 
for a more safe identification at the species level, other characteristics such as 
pyocyanin pigment formation, proteolytic activity, nitrate utilisation, lipolytic activity and 
glutamate utilisation need to be evaluated (Franzetti and Scarpellini, 2007). However, 
conventional identification based on serological, biochemical and culture on selective 
media are not practical methods for routine use (Busse et al., 1996). Additionally, 
misidentiﬁcations are commonly observed due to erroneous phenotypic descriptions 
inﬂuenced by cultivation conditions.  
 
1.5.2. Direct molecular identification 
New alternatives have been drawn and, in the last few years, molecular methods have 
been extensively used in bacterial identification. Molecular methods allow the definition 
of phylogenetic relationships among the organisms. However, the bacterial species 
concept remains under discussion in the scientific community. Bacterial species are 
usually defined based on the combination of several criteria (Vandamme et al., 1996; 
Stackebrandt et al., 2002). The criterion suggested by Wayne et al. (1987) has been 
widely used and still remains a reference. Wayne et al. state that an unknown strain is 
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considered to be a member of the same reference species when it shows 70% or 
greater DNA-DNA hybridization values. The above value for DNA–DNA hybridization 
grossly corresponds to 97% 16S rRNA sequence similarity (Brenner et al., 2001). Such 
relatedness must be employed for establishing relationships between microorganisms 
and phylogenetic analyses and surely allows outstanding classification of bacteria up to 
the genus level.  
 
1.5.2.1. 16S rRNA 
16S rRNA has been used for species identification (Wagner et al., 2008) as well as to 
Pseudomonas genus phylogenetic affiliation (Anzai et al., 2000; Purohit et al., 2003). 
One of the earliest studies based on the comparison of 16S rRNA sequences on 
Pseudomonas species grouped these bacteria into two groups: P. fluorescens and P. 
aeruginosa (Moore et al., 1996). Afterward, a study on more than 100 Pseudomonas 
species based on 16S rRNA sequence comparison, proposed the division of 
Pseudomonas species into seven groups (Figure 4) (Anzai et al., 2000). In the study, 
P. aeruginosa was proposed to be included in P. aeruginosa group along with 
Pseudomonas anguilliseptica, Pseudomonas resinovorans, Pseudomonas alcaligenes, 
Pseudomonas citronelloli, Pseudomonas nitroreducens, Pseudomonas oleovorans, 
Pseudomonas pseudoalcaligenes, Pseudomonas mendocina, Pseudomonas 
flavescens and Pseudomonas straminea. Although the sequencing of this gene is 
commonly used, discussion on the deprived resolution of the phylogenetic analysis with 
16S rRNA sequences lead to using other genes to characterise and classify 
Pseudomonas species (De Vos et al., 1998; Yamamoto et al., 2000; Bodilis et al., 
2004; Ait Tayeb et al., 2005).  
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Figure 4. Phylogenetic tree of the Pseudomonas species based on 16S rRNA gene sequence. The colours 
represent the different groups defined by Anzai (2000): pink - Pseudomonas syringae group; green - Pseudomonas 
chlororaphis group; blue - Pseudomonas fluorescens group; red - Pseudomonas putida group; brown - Pseudomonas 
stutzeri group; purple - Pseudomonas aeruginosa group; and orange – Pseudomonas percinogena group. 
Pseudomonas jessenii, Pseudomonas agarici. Pseudomonas fuscovaginae and Pseudomonas asplenii are strains that 
do not belong to any previously defined group. Adapted from Anzai et al., 2000 .  
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1.5.2.2. Multilocus sequence analysis  
The genes rpoB, gyrB and rpoD are good alternatives to 16S rRNA gene for 
identification of P. aeruginosa (Yamamoto et al., 2000; Ait Tayeb et al., 2005). These 
genes present higher number of base substitutions than 16S rRNA gene. The 
concatenated of multiple genes significantly increases the discriminating power of 
molecular identification methodologies.  
Multilocus sequence analysis (MLSA) has been suggested as excellent alternative to 
DNA-DNA hybridisation and 16S rRNA (Martens et al., 2008). It allows a phylogenetic 
characterisation using allele sequences of various genes, which permits the delineation 
of several species. This tool is capable of yielding sequence sets at an extensive range 
of taxonomic levels, from intraspecific through the species level to sets at higher levels. 
Frapolli used ten housekeeping genes for evaluating the phylogeny of some 
Pseudomonas species (Frapolli et al., 2007). A better definition and delimitation of the 
various species requires a consistent understanding of the breadth and the genetic 
differences between closely related forms (Konstantinidis and Tiedje, 2005; Almeida 
and Araujo, 2013). Thereby, it is necessary an extensive characterisation of several 
bacterial groups at high resolution level.  
 
1.6. Genotyping of Pseudomonas aeruginosa 
Genotyping plays an important role to examine the widest range of genetic variation 
among bacteria. Through genotyping it is possible to monitor the evolution, determine 
the source of infection, recognise disease outbreaks as well as detect cross-
transmission of pathogens.  
Bacterial typing has been performed by different molecular methods providing 
measures of genetic diversity (Li et al., 2009). Some examples of these methods are: 
enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR), pulsed-field gel 
electrophoresis (PFGE) and random amplified polymorphic DNA (RAPD). These three 
methods capture a genome-wide perspective on diversity between strains by 
employing different approaches (Kidd et al., 2010; Waters et al., 2012). Methods, 
such as ERIC-PCR and RAPD, have the advantage of being practical, fast, and 
consequently more amenable to high-throughput typing than others, such as 
PFGE. PCR-based methods may also be developed to a rapid diagnosis of 
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epidemic clonal strains (Lewis et al., 2005; Johnson et al., 2007; Williams et al., 
2010a). One downside of these methods is that the number of P. aeruginosa 
strains with the same profile may be overestimated using ERIC-PCR and RAPD, 
thus these methodologies presenting lower discriminatory power. Therefore, an 
additional typing methodology may be required to confirm the relationships 
between indistinguishable types. PFGE is a molecular fingerprinting technique based 
on restriction sites within the bacterial genome and presents a discriminatory power 
of 0.980. Nevertheless, the equipment required for PFGE is extremely expensive and 
the time spent and reproducibility represent main concerns for the method. 
 
1.6.1. Multilocus sequence typing  
Multilocus sequence typing (MLST) of bacteria has become well-known and nowadays 
there are more than 40 developed schemes for bacterial genotyping. This method 
represents a powerful tool that allows genotyping microbial isolates (Curran et al., 
2004; Baldwin et al., 2005) and population structure studies (McManus et al., 2008). 
Additionally, MLST also may occasionally identify evidence of recombination by the 
presence of multiple nucleotide substitutions in close related isolates or  the occurrence 
of the same alleles in unrelated isolates within the same data set (Bolt et al., 2010). 
This technique compares sequences of nucleotides between 400-500 bp usually of five 
to seven housekeeping genes (Li et al., 2009). MLST combines several advantages, 
including reproducibility, the production of unambiguous datasets and the possibility to 
compare and transfer data between different laboratories worldwide through a shared 
central database (http://www.mlst.net/) (Jolley et al., 2004; Griffiths et al., 2010). In 
2004, MLST was applied to P. aeruginosa by Curran et al. (2004). On this scheme 
seven housekeeping genes of P. aeruginosa were selected for genotyping this species. 
Partial gene sequences of acetyl coenzyme A synthetase (acsA), shikimate 5-
dehydrogenase (aroE), guanosine 5’-monophosphate synthase (guaA), DNA mismatch 
repair protein (mutL), bifunctional NADH:ubiquinone oxidoreductase subunit C/D 
(nuoD), phosphoenolpyruvate synthase (ppsA) and anthranilate synthase component I 
(trpE) were selected. Nowadays, the information of about 1,500 P. aeruginosa strains 
is easily available online at the MLST website. P. aeruginosa MLST presents a high 
discriminatory power (above 0.975) and recently it has become an important alternative 
to the previous gold standard method for bacteria genotyping, the PFGE. However, the 
applicability of MLST is still limited to small collections due to the high cost and time 
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spent to complete the task. Hence, it is necessary to develop alternative methods that 
are able to facilitate such studies and to boost bacterial genotyping by allowing large-
scale analysis. In this context, the use of informative SNPs has been recently proposed 
as an alternative to the MLST. 
 
1.6.2. Single Nucleotide Polymorphisms  
The divergence between P. aeruginosa genomes is based mostly in SNP variation 
(Spencer et al., 2003). This form of genetic variation has a maximum of four alleles for 
each base and can be explored to study the diversity and dynamics of many 
populations, by selecting and combining several different SNPs simultaneously (Schork 
et al., 2000). SNP-based approaches use a range of genetic targets, similarly to MLST, 
and it has been demonstrated that SNP analysis combined with sequencing of short 
variable regions presents a similar discriminatory power as MLST analysis (Fothergill et 
al., 2010). Additionally, SNPs can be found very close to each other and the 
assessment of linkage disequilibrium may expose sites for recurrent mutation, gene 
conversion or even spots for recombination.  
Few SNP-based methods have been suggested for genome analysis of P. aeruginosa, 
including AT biochips, microarray typing device, High Resolution Melting curve-based 
SNP typing profile assay and SNaPaer. AT biochips (Hansen et al., 2012) are a good 
alternative for time consuming methods, such as MLST,  but they are limited by biochip 
fabrication steps as well as the expensive equipment necessary for the operation of 
this method. Another methodology based on microarray typing device was developed 
to analyse the population genetics of P. aeruginosa (Wiehlmann et al., 2007). This 
portable methodology analyses 16 SNPs of the core genome and 38 SNPs of flexible 
genome. However, this assay is based in a binary system, thus, if a different SNP 
appears wrong conclusions may be taken. High Resolution Melting curve-based SNP 
typing profile assay was developed by Anuj et al. (2011) to identify major clonal strains 
presented in CF patients of Brisbane, Australia. However, a previous study of High 
Resolution Melting revealed that this method incorrectly identified negative control 
samples, suggesting a problem with non-specific fluorescence (Vezenegho et al., 
2009).  
SNaPaer is a very recent approach that has been developed for genotyping of P. 
aeruginosa (Eusebio et al., 2013). Although the approach has been recently developed 
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for P. aeruginosa, it is based on the SNaPshot mini-sequencing technique which has 
been previously used in multiple organisms and with different objectives, such as 
comparison of strains (Huang et al., 2012), serotypes (Ben-Darif et al., 2010), virulent 
and epidemic clones (Lomonaco et al., 2011), phylogenetic related sub-groups of 
isolates (Huang et al., 2011), as well as identification of various species (Kristensen et 
al., 2007; Bouakaze et al., 2010; Wang et al., 2010). 
 
1.6.3. SNaPaer - SNaPshot mini-sequencing scheme 
SNaPaer assay is a useful and low-cost molecular method that uses a set of 23 
polymorphisms for a rapid genotyping of P. aeruginosa. The 23 neutral genetic 
polymorphisms are located on the seven housekeeping genes suggested for P. 
aeruginosa MLST  and represent a theoretical number of combinations of up 15 billion 
(Eusebio et al., 2013). SNaPaer assay employs SNaPshotTM kit commercialised by 
Applied Biosystems, which allows that multiple reactions be performed simultaneously 
(Figure 5). Mini-sequencing follows the amplification of the seven housekeeping genes 
and involves the addition of an extension primer (or a set of primers) with a tail in 5’ 
extreme (one base upstream to the target SNP). Then, a single base extension 
reaction is executed in the presence of the fluorescently labeled ddNTPs that are 
excited with a laser. The use of primers with different tails in 5’ extreme allows the 
recognition of multiple fragments from extension reaction. The fluorescence-labelled 
primer extension product is subsequently separated by capillary electrophoresis and 
analysed. As result, it is constructed a panel with peaks of different colour and length. 
The colour of the peak represents the nucleotide site-specific variation; the location 
corresponds to the size of the fragment, which is associated with the locus and position 
of the SNPs. To the ordered set of 23 SNPs (in accordance with MLST data sets) we 
gave the name of SNaP profile. Some of the biggest advantages of mini-sequencing 
include the possibility of using very small PCR products (thereby markers may work 
with extremely degraded DNA samples), the absence of stutter products and the 
flexibility to accept the replacement or addition of new markers.  
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Figure 5. SNaPaer genotyping for Pseudomonas aeruginosa. SNaPaer uses SNaPshot technology, which involves 
multiplexed amplification of the seven housekeeping genes in a single multiplex reaction (A), multiplexed single-base 
primer extension with fluorescently-labelled ddNTPs of 23 SNPs in a single mini-sequencing assay (B), and analysis of 
labelled-primer extension products by capillary electrophoresis (C).  
A 
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2. Aims 
 
Some studies have already described the evolution, diversity and mutation rates for P. 
aeruginosa collected from CF patients (Huse et al., 2010; Mowat et al., 2011; Chung et 
al., 2012). Nevertheless, few studies have been reported in non-CF bronchiectasis and 
many questions still remain unanswered. Is P. aeruginosa adapting similarly in the lung 
of chronic non-CF and CF bronchiectasis patients? What happens to bacterial 
populations in the lung that leads to exacerbations (acute condition) in patients with 
bronchiectasis? What is the diversity of P. aeruginosa strains in patients with 
bronchiectasis and what are the consequences of such diversity? Is therapy altering 
the diversity of strains in the bronchiectasis lung?  
It is imperative to define the clinical situations that can benefit from the application of 
molecular methods to a fast and robust diagnosis. SNaPaer assay was developed for 
genotyping of P. aeruginosa and the specificity of the multiplex should be high due to 
presence of the 23 loci. Is this method also capable to identify these bacteria in control 
and clinical samples?  
The present study aims to:  
I. test the taxonomic power of MLST sequences and SNaPaer assay to identify P. 
aeruginosa amongst related species; 
II. identify and genotype P. aeruginosa in clinical samples collected from patients with 
bronchiectasis;  
III. compare P. aeruginosa colonisation in patients diagnosed with non-CF and CF 
bronchiectasis.  
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3. Materials and methods 
 
3.1. Phylogeny of Pseudomonas genus based on multilocus 
sequence typing data 
The MLST scheme has previously been shown to be useful for species identification 
(Maiden, 2006). Here, we proposed to test the capability of the MLST method for 
Pseudomonas species identification. Therefore, 50 complete genomes of 
Pseudomonas species available at NCBI database were downloaded to an in-house 
record (Table 1). The sequences of the genes acsA, aroE, guaA, mutL, nuoD, ppsA 
and trpE similar to P. aeruginosa MLST were identified in each genome using 
Geneious Pro 6.0.6 software. Gene nuoD could not be found in the genomes of the 
following strains: Pseudomonas stutzeri A1501, Pseudomonas stutzeri ATCC 17588, 
Pseudomonas stutzeri CCUG, Pseudomonas stutzeri DSM and Pseudomonas stutzeri 
RCH2. Therefore, these genomes were excluded in some of the phylogenetic 
analyses. MLST genes were aligned in Geneious, using Clustal W (Thompson et al., 
1994). Phylogenetic trees were constructed using the neighbourjoining (NJ) method 
(Saitou and Nei, 1987) and the genetic distances were computed using the Maximum 
Composite Likelihood model. Bootstrap values were calculated for tree nodes.  
The 23 SNPs (SNaP profile) suggested by Eusebio et al. (2013) for genotyping of P. 
aeruginosa were identified in the MLST sequences for the 45 Pseudomonas species 
genomes. The resulting set of 45 SNaP profiles was included in a database in addition 
to the group of 86 SNaP profiles obtained from a previous study of Eusebio et al. 
(2013). Subsequently, all SNaP profiles were converted into preMLST sequences using 
MLST@SNaP software (Soares and Araujo, 2013). Finally, the phylogenetic trees were 
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reconstructed and compared with previously reported phylogenetic trees (Anzai et al., 
2000; Yamamoto et al., 2000; Ait Tayeb et al., 2005). 
Table 1. List of genomes of Pseudomonas strains analysed in this work, downloaded from the NCBI database.  
Name Group* Accession Length 
Chromohalobacter salexigens DSM 3043 Not applicable NC_007963 3,696,649 
Pseudomonas aeruginosa 19BR  Pseudomonas aeruginosa AFXJ01000001 6,742,964 
Pseudomona aeruginosa 213BR  Pseudomonas aeruginosa AFXK01000001 6,719,211 
Pseudomonas aeruginosa 39016 Pseudomonas aeruginosa NZ_CM001020 6,866,064 
Pseudomonas aeruginosa 9BR 9BRScaffold1 Pseudomonas aeruginosa AFXI01000001 6,801,503 
Pseudomonas aeruginosa DK2 Pseudomonas aeruginosa CP003149 6,402,658 
Pseudomonas aeruginosa LESB58  Pseudomonas aeruginosa NC_011770 6,601,757 
Pseudomonas aeruginosa M18  Pseudomonas aeruginosa NC_017548 6,327,754 
Pseudomonas aeruginosa NCGM2,S1 DNA Pseudomonas aeruginosa AP012280 6,764,661 
Pseudomonas aeruginosa PA7  Pseudomonas aeruginosa NC_009656 6,588,339 
Pseudomonas aeruginosa PACS2 Pseudomonas aeruginosa AAQW01000001 6,492,423 
Pseudomonas aeruginosa PAO1 Pseudomonas aeruginosa AE004091 6,264,404 
Pseudomonas aeruginosa UCBPP-PA14 Pseudomonas aeruginosa CP000438 6,537,648 
Pseudomonas brassicacearum subsp, brassicacearum 
NFM421  
Not applicable NC_015379 6,843,248 
Pseudomonas chlororaphis O6 Pseudomonas chlororaphis  NZ_CM001490 6,980,251 
Pseudomonas chlororaphis subsp, aureofaciens 30-84  Pseudomonas chlororaphis  NZ_CM001559 6,666,321 
Pseudomonas entomophila L48  Pseudomonas putida NC_008027 5,888,780 
Pseudomonas fluorescens F113 Pseudomonas fluorescens  CP003150 6,845,832 
Pseudomonas fluorescens Pf0-1 Pseudomonas fluorescens  CP000094 6,438,405 
Pseudomonas fluorescens SBW25  Pseudomonas fluorescens  NC_012660 6,722,539 
Pseudomonas fluorescens SS101  Pseudomonas fluorescens  AHPN01000001 6,179,443 
Pseudomonas fluorescens A506  Pseudomonas fluorescens  NC_017911 5,962,570 
Pseudomonas fluorescens Q2-87  Pseudomonas fluorescens  NZ_CM001558 6,368,168 
Pseudomonas fluorescens Q8r1-96  Pseudomonas fluorescens  NZ_CM001512 6,602,611 
Pseudomonas fluorescens R124  Pseudomonas fluorescens  NZ_CM001561 6,256,692 
Pseudomonas fluorescens WH6  Pseudomonas fluorescens  NZ_CM001025 6,270,867 
Pseudomonas fulva 12-X  Pseudomonas putida NC_015556 4,920,769 
Pseudomonas mendocina NK-01  Pseudomonas aeruginosa NC_015410 5,434,353 
Pseudomonas mendocina ymp  Pseudomonas aeruginosa NC_009439 5,072,807 
Pseudomonas protegens Pf-5 Not applicable CP000076 7,074,893 
Pseudomonas putida CSV86 Pseudomonas putida NZ_AMWJ01000000 6,469,780 
Pseudomonas putida DOT-T1E  Pseudomonas putida NC_018220 6,260,702 
Pseudomonas putida GB-1 Pseudomonas putida CP000926 6,078,430 
Pseudomonas putida KT2440  Pseudomonas putida NC_002947 6,181,863 
Pseudomonas putida ND6  Pseudomonas putida NC_017986 6,085,449 
Pseudomonas putida UW4  Pseudomonas putida NC_019670 6,183,388 
Pseudomonas putida BIRD-1  Pseudomonas putida NC_017530 5,731,541 
Pseudomonas putida F1  Pseudomonas putida NC_009512 5,959,964 
Pseudomonas putida HB3267 Pseudomonas putida NC_019905 5,875,750 
Pseudomonas putida S16  Pseudomonas putida NC_015733 5,984,790 
Pseudomonas putida W619  Pseudomonas putida NC_010501 5,774,330 
Pseudomonas stutzeri A1501  Pseudomonas stutzeri  NC_009434 4,567,418 
Pseudomonas stutzeri CCUG 29243  Pseudomonas stutzeri  NC_018028 4,709,064 
Pseudomonas stutzeri DSM 10701  Pseudomonas stutzeri  NC_018177 4,174,118 
Pseudomonas stutzeri DSM 4166  Pseudomonas stutzeri  NC_017532 4,689,946 
Pseudomonas stutzeri ATCC 17588 = LMG 11199  Pseudomonas stutzeri  NC_015740 4,547,930 
Pseudomonas stutzeri RCH2 Pseudomonas stutzeri  NC_019939 4,575,057 
Pseudomonas synxantha BG33R  Pseudomonas fluorescens NZ_CM001514 6,297,495 
Pseudomonas syringae pv, phaseolicola 1448A  Pseudomonas syringae  NC_005773 5,928,787 
Pseudomonas syringae pv, syringae B728a Pseudomonas syringae  NC_007005 6,093,698 
Pseudomonas syringae pv, tomato str, DC3000 Pseudomonas syringae  AE016853 6,397,126 
* Suggested by Anzai et al., 2000. 
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3.2. SNaPaer assay for identification of Pseudomonas aeruginosa 
MLST gene amplification was tested in various strains of Pseudomonas species, 
including 12 clinical strains of P. aeruginosa  from our collection and P. putida KT2440, 
P. fluorescens Pf0-1, P. savastanoi pv. glycinea 5066, P. savastanoi pv. phaseolicola 
2245, P. syringae pv. helianthi 5067, P. syringae pv. maculicola 5071, P. syringae pv. 
oryzae 10912, P. syringae pv. syringae 10604, P. syringae pv. tabaci 5393 and P. 
syringae pv. tomato DC 3000. Two strains of Xanthomonas, X. axonopodis pv. citri 
9322 and  X.  campestris pv. campestris 568, and six clinical strains of Burkholderia 
cenocepacia were also included. Some of these strains were provided by Doctor 
Fernando Tavares (Faculty of Sciences, University of Porto).  
MLST was performed in 30 strains using the primers previously described by Eusebio 
et al. (2013) (Table 2). Multiplex touchdown PCR was conducted in a final volume of 5 
μL, containing 2.5 μL of Qiagen multiplex PCR master mix (Qiagen), 1 μL of bacterial 
DNA, 0.5 μL of primer mix (each primer at 2 μM), 0.5 μL of Q-solution (Qiagen) and 0.5 
μL of ultrapure water. Thermalcycling conditions were the following: denaturation for 15 
min at 95 ºC; 3 cycles with denaturation for 1 min at 95 ºC, primer annealing for 30 s at 
63 ºC and extension for 2 min at 72 ºC; 3 cycles with denaturation for 1 min at 95 ºC, 
primer annealing for 30 s at 61 ºC and extension for 2 min at 72 ºC; 3 cycles with 
denaturation for 1 min at 95 ºC, primer annealing for 30 s at 59 ºC and extension for 2 
min at 72 ºC; 26 cycles with denaturation for 1 min at 95 ºC, primer annealing for 30 s 
at 57 ºC and extension for 2 min at 72 ºC; and final extension for 10 min at 72 ºC. 
Amplicon sizes were evaluated after separation by polyacrylamide gel electrophoresis 
and standard silver-staining detection (Qu et al., 2005).  
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Table 2. Primers used for Pseudomonas aeruginosa MLST. 
Locus Primer sequence (5’ to 3’) Amplicon size (bp) 
acsA 
Forward* CTGGTGTACGCCTCGCTGAC 
837 
Reverse TAGATGCCCTGCCCCTTGAT 
aroE 
Forward TATTCGGCAACCCCATCG 747 
Forward* ACGATTTCCCCGGGTTC 
642 
Reverse CGCGCCAGAGGAAGAAT 
guaA 
Forward* CGGCCTCGACGTGTGGATGA 
844 
Reverse GAACGCCTGGCTGGTCTTGTGGTA 
mutL 
Forward AGCCTGGCAGGTGGAAAC 
634 
Reverse* CAGGGTGCCATAGAGGAAGTC 
nuoD 
Forward* ACCGCCACCCGTATCTG 
1080 
Reverse TCTCGCCCATCTTGACCA 
ppsA 
Forward* GGGTAGCAAGGCGATCAAGATG 
1064 
Reverse GGTTCTCTTCTTCCGGCTCGTAG 
trpE 
Forward* GCCGATCCCTCCGAGGAAAATG 
993 
Reverse CCCGGCGCTTGTTGATGGTT 
* Primers used for sequencing. 
 
SNaPaer assays was performed in 30 strains using the primers of Table 3 and carrying 
out a final volume of 5 μL, containing 1.5 μL of PCR product (purified with Escherichia 
coli exonuclease I and shrimp alkaline phosphatase (ExoSAP-IT®) (USB® Products; 
Affymetrix), according to the manufacturer’s protocol), 1 μL of SNaPaer primer mix 
(each primer at 1 μM), 1 μL of ABI Prism SNaPshot® Multiplex Kit (Applied 
Biosystems), and 1.5 μL of ultrapure water (Eusebio et al., 2013). The reaction mixture 
was run with 25 extension cycles in the following conditions: denaturation for 10 s at 96 
ºC, primer annealing for 5 s at 50 ºC, and extension for 30 s at 60 ºC. Unincorporated 
ddNTPs were removed with 1 U of Shrimp Alkaline Phosphatase (SAP) (USB® 
products) following incubation for 1 h at 37 °C and 15 min at 85 °C, as suggested by 
the manufacturer. SNaPaer products (0.5 μL) were mixed with 9.0 μL of HiDiTM 
formamide (Applied Biosystems) and 0.5 μL of GeneScan-120 LIZ size standard 
(Applied Biosystems). Electrophoresis was performed on a 3130xl Genetic Analyzer 
(Applied Biosystems) using filter set E5. Data were analysed with the software 
GeneMapper v4.0 (Applied Biosystems). 
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Table 3. Primers used for SNaPaer. 
 
Name Expected SNP  Primer sequence (5’ to 3’) Expected lenght 
Ac7 A/C/T CCTACATCGTCTATGGYCCG 75-76 
Ac78 A/G TGACCCGCGTGGCGAA 33-34 
Ac336 A/C/T GCCCGGCTTCATCGC 68-69 
Ac387 A/C/G GCCGAGGTTGTCCACCAG 106-107 
A98 C/G/T GAACACCCTGATCCGCCT 50-52 
A264 C/G/T CGGTTGGCGATCAGCA 26-27 
A491 C/G/T ATGTAYGSCAAGGAACCGAC 95-96 
G6 A/C/G/T GGTTCCTCCAAGGTCCTGCT 70-71 
G49 A/C/G/T CCGATGGCCTTGTGCA 62-63 
G219 C/T TTGCGCTTCTCTTCCGG 46-47 
G264 A/C/G/T GGCCGCGCTTTCATCGAAGT 40-41 
M9 A/G GCCAGGCGCTTGATGAC 59-61 
M36 C/G/T GTGGAAAGCCACGTCGAA 80-82 
M204 G/C/T GCCTGCACCTGTGGGG 53-55 
M228 A/C/G/T CAGGTCCGGCTGGCTGCG 92-93 
N162 C/T CCAGTCCTGGCACAGTTTCAT 35-37 
N255 C/G GCCGGGATCAAGGTGCC 57-58 
N288 C/G/T GGTTCAGGATRCGGAAGAACTC 98-99 
P100 A/C/G/T GCTGGCCGATGGCACG 85-87 
P268 A/C/G/T GTCACCAACCGAGGAGGGCG 48-49 
T205 C/G/T TGGGGCGGGTGTCCGA 101-102 
T331 A/C/T ACGCGCTGCGGGCGAT 77-78 
T349 A/G TGCCGGCGGGYACKCT 107- 109 
 
3.3. Patient population 
P. aeruginosa can be easily isolated from bronchiectasis patients on Cetramide agar 
plates. The study of P. aeruginosa strains from these patients is valuable to understand 
how bacterial population changes over time and from patient to patient.  
A total of 29 patients diagnosed with bronchiectasis, admitted at Hospital São João 
(Porto, Portugal) and Hospitais Universitários Coimbra (Coimbra, Portugal), were 
recruited for this study: 11 patients were classified as presenting non-CF 
bronchiectasis and 18 presented CF bronchiectasis. Bronchiectasis was diagnosed by 
HRCT together with other characteristic symptoms such as chronic cough, bad breath 
and sputum production. Genotype, sweat (chloride) test, organ function tests, and 
exercise testing were considered for the diagnosis of CF. Personal information and 
clinical history of each patient was also registered: age, gender, history of exacerbation 
and antibiotic treatments, bacterial colonisation, PF, FEV1, FEV/FVC (Forced Vital 
Capacity) ratio, radiographic abnormality and total serum IgE >500 IU/mL (1200 
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ng/mL), bronchiectasis type (localised or diffused), C-reactive protein, haemoptysis and 
other associated diseases.  
 
3.4. Pseudomonas aeruginosa culture and sampling 
Biological secretions and/or bronchial aspirates were collected every 2-4 months 
(between 2009 and 2012) from our group of patients. Patient specimens (sputa) were 
cultured twice on Petri dishes with Cetrimide Agar plates for the detection and culture 
of P. aeruginosa. The plates were incubated at 37ºC for a period of 48-72 h. Selected 
bacterial colonies observed in Cetrimide Agar plates were re-cultured in new plates. 
The results of this procedure were compared with previously reported results from the 
hospital.  
The selection of bacterial colonies was random using a transparent paper with a 
fractionated matrix as presented in Figure 6. Afterwards, eight sections were selected 
using the R command: sample(1:38,8,replace=F), from the R Gui v2.15.2 (R 
Development Core Team). Multiple results for the samples used are shown in Annex 1. 
Isolated colonies closest to the centre of the square were selected; if the selected 
square did not contain an isolated colony, the adjacent square was chosen. 
Additionally, few strains collected from CF patients with bronchiectasis from a previous 
study (Eusebio et al., 2013) were also added to the collection. Phenotypic 
characteristics of bacteria, such as type (mucoid, rough or smooth) and pigmentation, 
were registered. A total of 53 clinical samples were tested from 29 patients and 207 
colonies of P. aeruginosa were obtained for further genotyping analysis. 
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Figure 6. Selection of eight colonies for molecular studies. A: Random selection of eight colonies (blue spots) 
previous cultured in a Cetramide plate. B: Re-culturing of the previous selected colonies. 
 
3.5. Sample Colony-PCR preparation 
MLST amplification was performed in 207 isolates of P. aeruginosa as previously 
reported (Eusebio et al., 2013); the MLST housekeeping genes have been previously 
described by Curran et al. (2004) but, the initial step that follows bacterial isolation and 
that includes the extraction of bacterial DNA from cells was avoided. Bacterial colonies 
were used directly for MLST amplification. Three different strategies were tested:  
 
3.5.1. Colony direct-PCR 
A small amount of bacteria was re-suspended and vortexed in an Eppendorf tube 
containing 10 µL of ultrapure water. Bacterial suspensions were incubated at 95 ºC for 
90 min. Afterwards, the suspension was vortexed and stored at -20 ºC. 
 
3.5.2. Pre-incubation with Genomiphi 
The commercial IlustraTM GenomiPhi V2 DNA Amplification Kit (GE Healthcare) was 
used. A small amount of bacteria from a single colony was added to 10 µL of sample 
buffer, as previous described to colony direct-PCR. The mixture was heated during 90 
min, at 95 ºC. For the amplification reaction, 9 µL of reaction buffer and 1 µL of enzyme 
mix were added to the bacterial product. The final 20 µL were incubated according to 
the following conditions: amplification for 120 min, at 30 ºC; inactivation of the Phi29 
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DNA polymerase enzyme for 10 min, at 65 ºC; and a final step of cooling at 4 ºC. The 
mixture was stored at -20 ºC. 
 
3.5.3. Pre-treatment with Proteinase K 
A small amount of bacteria was added to 20 µL ultrapure water as described above for 
colony direct-PCR. The mixture was vortexed and heated for 60 min, at 95 ºC and 2 µL 
of Proteinase K (2 mg/mL) (Finnzymes) were then added to the previous mixture. After 
a short spin, the mixture was incubated for 60 min at 56ºC. The inactivation of 
Proteinase K was performed following vortexing and heating for 8 min, at 100º C. 
Subsequent centrifugation was performed at 14,000 rpm for 4 min. The finally mixture 
was stored at -20 ºC. 
 
3.6. Genotyping of Pseudomonas aeruginosa strains from 
bronchiectasis patients 
MLST genes of the previous mentioned 207 P. aeruginosa Portuguese strains were 
amplified and the bacteria genotyped as previously suggested by Eusebio et al. (2013). 
PCR amplification with pre-treatment with Proteinase K was selected due to the 
efficiency of the method. PCR fragments were also sequenced to confirm their 
specificity. Thus, amplification products were purified with ExoSap-IT®, according to 
the manufacturer’s protocol. Sequencing was performed using the ABI BigDye® 
terminator v3.1 cycle sequencing ready reaction kit (Applied Biosystems). PCR 
sequencing conditions were: denaturation for 2 min at 96 ºC; 35 cycles with 
denaturation for 15 s at 96 ºC, primer annealing for 9 s at 50 ºC and extension for 2 min 
at 60 ºC; final extension for 10 min at 60 ºC. The product was purified with Sephadex® 
(Expansys). A volume of 8.0 μL HiDiTM formamide (Applied Biosystems) was added to 
each PCR product before sequencing.  
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3.7. Analyses of the genotyping data 
SNaPshot results were analysed in GeneMapper® Software v4.0 and Peak ScannerTM 
software v1.0, both afforded by Applied Biosystems and the sequencing data were 
analysed with Sequence ScannerTM v1.0 and Geneious Pro 5.5.6 softwares.  
The Network software v4.6.1.0 (www.fluxus-engineering.com/sharenet.htm) (Polzin 
and Daneschmand, 2003) was used to better visualise the relations of the several 
haplotypes from the populations genotyped in the present work.  
For the contextualisation of the genetic patterns observed in the studied populations, 
additional data were retrieved from the literature and databases available online. Data 
for the 23 SNPs were extracted from Pseudomonas aeruginosa MLST Database 
(http://pubmlst.org/paeruginosa/).  
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4. Results 
 
4.1. Pseudomonas species phylogeny based on MLST data 
Phylogenetic analysis for 50 Pseudomonas species was carried out using data for 
acsA, aroE guaA, mutL, nuoD, ppsA and trpE gene fragments, previously reported for 
P. aeruginosa MLST (Curran et al., 2004). Four other genes, 16S rRNA (Anzai et al., 
2000), gyrB and rpoD (Yamamoto et al., 2000) and rpoB (Ait Tayeb et al., 2005), 
previously suggested for Pseudomonas species identification were identified in this list 
of genomes (Table 2). The GC content of the genes was between 48.6% (for gyrB) and 
66.9% (for acsA), with an average of 61.2% for all loci (Table 4).  
 
Table 4. General characterisation of genes collected from Pseudomonas species genomes. 
Locus 
Size analysed 
sequence (bp) 
Number of 
alleles 
% GC 
content 
Number of identical sites 
(%) 
MLST genes     
acsA 390 50 66.9 208 (53.3) 
aroE 498 50 66.0 185 (37.1) 
guaA 373 50 63.6 245 (65.7) 
mutL 442 50 65.5 239 (54.1) 
nuoD* 366 45* 61.8 256 (69.9) 
ppsA 370 50 65.4 221 (59.7) 
trpE 443 50 63.4 258 (57.5) 
     
Other genes     
16S rRNA 1456 50 52.0 1,114 (73.2) 
gyrB 2421 50 48.6 1,350 (55.2) 
rpoB 1149 50 61.0 815 (70.5) 
rpoD 1854 50 59.2 1,129 (60.2) 
* The gene nuoD was not detected on five Pseudomonas stutzeri genomes.  
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The strain Chromohalobacter salexigens DSM 3043 was used as an out-group,  to 
define the root of the phylogenetic trees, as the genus Chromohalobacter is 
phylogenetically related to Pseudomonas species (Williams et al., 2010b).  
Phylogenetic trees (NJ) for individual data sets of acsA, aroE, mutL, nuoD, guaA, ppsA, 
and trpE nucleotide sequences were constructed (Annex 5 - Annex 12). The single-
locus topologies of MLST genes showed well-defined groups for P. chlororaphis, P. 
stutzeri, and P. syringae; P. putida strains formed single clusters with two or three 
exceptions dispersed in other groups, while the strains of P. fluorescens were 
dispersed throughout the trees. P. aeruginosa group was well-defined in acsA 
phylogeny; however, the remaining single locus phylogenies defined P. mendocina 
strains outside the P. aeruginosa group. The aroE phylogenetic tree presented the 
highest boot strap values for separating of three previously defined groups (P. 
chlororaphis, P. stutzeri, and P. syringae), while nuoD phylogenetic tree showed the 
lowest phylogenetic value defining only a cluster for P. syringae. The resolution of 
these phylogenetic trees may be justified by nucleotide diversity as aroE was the most 
polymorphic gene with only 37.1% of identical sites (the number of consensus positions 
obtained from the alignment of the various sequences of each gene). In contrast, nuoD 
was the least polymorphic gene with a percentage of identical sites of 69.9%.  
Concatenated gene sequences were used to construct MLST phylogenies: a) the first 
phylogeny with all seven MLST genes but excluding the five strains of P. stutzeri with 
no nuoD gene (Figure 7); and b) a second phylogeny with acsA, aroE, guaA, mutL, 
ppsA and trpE genes of all the tested strains (Annex 12). The basic topologies of both 
trees were similar, the most visible difference between these phylogenetic trees being 
on the bootstrap values, which were slightly higher in some branches of the seven 
genes phylogeny. When compared the seven and six concatenated phylogenies with 
single locus phylogenies, we verified a substantially increase of the bootstrap values 
for definition of P. putida group. The definition of the remaining groups was similar in 
concatenated and single locus phylogenies. Figure 7 shows the phylogeny of acsA, 
aroE, guaA, mutL, nuoD, ppsA and trpE concatenated genes and includes all strains 
presented in Table 1 with exception of some P. stutzeri. In both phylogenies was 
possible to clearly define groups for strains of P. chlororaphis, P. stutzeri and P. 
syringae, with bootstrap values of 100. The P. aeruginosa group was divided in two 
separated clusters with most strains of P. aeruginosa separated from P. mendocina 
strains. P. putida group was well-defined for 11 out of the 13 strains on this group; P. 
fulva 12-X and P. putida UW4 were far from the group. P. fluorescens strains formed a 
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well-defined group in the phylogeny that considered the six concatenated genes, 
although with a very low bootstrap value (59.8%). Additionally, within this group,  was 
possible to observe P. brassicacearum NFM421, not defined as belonging to any of the 
previous groups (Anzai et al., 2000).  
In order to understand the importance of the concatenated sequences of the acsA, 
aroE, guaA, mutL, nuoD, ppsA and trpE genes for improving the resolution of the 
phylogeny of some species within the Pseudomonas genus, the phylogenetic trees of 
16S rRNA (Annex 2), rpoB gene (Annex 3) and concatenated rpoD and gyrB genes 
(Annex 4) were designed for the same list of strains. The phylogenies obtained were 
very similar to those previously suggested by other authors (Anzai et al., 2000; 
Yamamoto et al., 2000; Ait Tayeb et al., 2005). The tree of 16S rRNA showed the 
lowest resolution. In rpoD and gyrB concatenated and rpoB phylogenies, P. fulva 12-X 
and P. putida UW4 were not clustered within the P. putida group as previously shown 
with MLST data. These last phylogenies were similar but the rpoD and gyrB 
concatenated phylogeny showed the highest bootstrap values. 
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Figure 7. Phylogenetic tree of 50 Pseudomonas species based on concatenated acsA, aroE, guaA, mutL, nuoD, 
ppsA and trpE genes. The tree was constructed using the neighbourjoining method and using Chromohalobacter 
salexigens DSM 3043 as an out-group. The number next to each node indicates the percentage bootstrap values for 
500 replicates. The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri 
group; purple - Pseudomonas aeruginosa group; red - Pseudomonas putida group; pink - Pseudomonas syringae 
group; green - Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens 
Pf-5 and Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group. 
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4.2. Identification of Pseudomonas aeruginosa by SNaPaer 
The potential of SNaPaer for identification of P. aeruginosa was also evaluated. 
Initially, the 23 SNPs (SNaP profile) suggested by Eusebio et al. (2013) for P. 
aeruginosa genotyping were identified in silico in the list of 45 Pseudomonas 
genomes (see Table 1); the strains with no nuoD gene were excluded. These 
SNaP profiles were added to a database that included other 86 SNaP profiles 
obtained from a previous study with clinical P. aeruginosa isolates (Eusebio et al., 
2013). All SNaP profiles were converted into preMLST sequences using 
MLST@SNaP software (Soares and Araujo, 2013). This programme uses an 
algorithm that converts the SNaP profiles into a probable MLST sequence 
(preMLST) based on the complete MLST data available for P. aeruginosa in the 
pubMLST website. By concatenating the seven preMLST sequences, a frame of 
2,882 bp was obtained for each tested strain of our list. The comparison between 
preMLST and published MLST sequences revealed a percentage of identical sites 
ranging from 77 to 85% among non-aeruginosa Pseudomonas species (the 
percentage was frequently close to 100% for P. aeruginosa strains). 
Phylogenetic analysis of the 45 preMLST sequences was performed (Figure 8). The 
tree resulting from the analysis was highly different from the one resolved by complete 
MLST sequences. In Figure 8 is possible to delineate a cluster of P. aeruginosa strains 
with a bootstrap value of 74%. However, two strains of P. aeruginosa (PA7 and PAO1) 
formed another cluster with a bootstrap value of 100%. In order to understand if these 
strains represented exceptional cases, 86 different SNaP profiles obtained from our 
collection of P. aeruginosa were added to the phylogeny. The new phylogeny 
allocated the 86 strains into the same cluster containing the remaining P. 
aeruginosa strains, with the exception of PA7 and PAO1 (data not shown). The P. 
aeruginosa PAO1 and PA7 presented the lowest values of identical sites when 
comparing preMLST and MLST sequences, with similarity values of 88.0% and 86.7% 
respectively, and represented atypical strains of P. aeruginosa. 
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Figure 8. Phylogenetic tree of 45 Pseudomonas species based on the concatenated preMLST sequences. The 
tree was constructed using the neighbourjoining method. The number next to each node indicates the percentage 
bootstrap values for 500 replicates. The purple colour represents the different strains of Pseudomonas aeruginosa. 
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4.3. Testing SNaPaer assay in non-aeruginosa Pseudomonas 
In order to test the suitability of SNaPaer assay for P. aeruginosa identification, the 
MLST housekeeping genes of 19 isolates from close-related bacterial species 
(Pseudomonas species, Xanthomonas species and Burkholderia cenopacia) were 
amplified. Several unspecific bands were observed in the polyacrylamide gel 
mainly following the amplification of MLST fragments in P. putida KT2440, P. 
fluorescens Pf0-1, P. savastanoi pv. glycinea 5066, P. syringae pv. oryzae 10912, P. 
syringae pv. syringae 10604, P. syringae pv. tabaci 5393 and X.  campestris pv. 
campestris 568 (Figure 9). With the exception of P. syringae pv. syringae 10604, the 
remaining isolates showed only one or two specific bands. B. cenocepacia isolates 
showed a complete absence of bands in the gel.  
In order to explain the low efficiency of MLST primers for amplification of these genes 
in non-aeruginosa species, the primer sequences were compared among the list of 
complete genome sequences (Table 1). The pair of primers with the highest level of 
polymorphisms was the set for nuoD sequence and the smallest number of 
polymorphism was found in guaA and ppsA primers (data not shown). Therefore, the 
presence of complete MLST profiles in the gel resulting from excellent MLST 
amplification could be the first indication of the presence of a P. aeruginosa isolate 
(numbered 1), as seen in Figure 9. 
 
 
 
 
 
 
 
 
Figure 9. Polyacrylamide gel of multilocus sequence typing fragments amplified by conventional PCR (L- ladder; 
1- Pseudomonas aeruginosa P7;  2- Pseudomonas putida KT2440; 3- Pseudomonas fluorescens Pf0-1; 4- 
Pseudomonas savastanoi pv. glycinea 5066; 5- Pseudomonas savastanoi pv. phaseolicola 2245; 6- Pseudomonas 
syringae pv. helianthi 5067; 7- Pseudomonas syringae pv. maculicola 5071; 8- Pseudomonas syringae pv. oryzae 
10912; 9- Pseudomonas syringae pv. syringae  10604; 10- Pseudomonas syringae pv. tabaci 5393; 11- Pseudomonas 
syringae pv. tomato DC 3000; 12- Xanthomonas axonopodis pv. citri 9322; 13- Xanthomonas  campestris pv. 
campestris  568; 14- Burkholderia cenocepacia 4201; 15- Burkholderia cenocepacia 4219; 16- Burkholderia 
cenocepacia 4203; 17- Burkholderia cenocepacia 4164; 18- Burkholderia cenocepacia 4178; 19- Burkholderia 
cenocepacia 4234). 
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Some P. aeruginosa reference strains (e.g. PAO1 and ATCC 33358) and other P. 
aeruginosa clinical isolates showed MLST gene amplification problems. Different 
annealing temperatures were tested going from 50 ºC to 54 ºC (Annex 13). Those 
genes could be amplified at lower temperatures; therefore, they were sequenced in 
order to confirm its specificity. The sequences were compared with the MLST genes of 
P. aeruginosa PAO1 and P. mendocina ymp. In this first analysis, it was verified that 
some genes of few P. aeruginosa strains and atypical clinical isolates were more 
similar with P. mendocina ymp strains than with P. aeruginosa PAO1. However, the 
concatenated of the MLST genes confirmed that such isolates were P. aeruginosa and 
distinct from P. mendocina. P. aeruginosa ATCC 33358 was an example of a strain 
showing a few polymorphisms in acsA but several polymorphisms in guaA genes (more 
than 20% when compared with the reference P. aeruginosa PAO1 available at NCBI) 
(Annex 14).  
SNaPaer primers were tested in non-aeruginosa bacteria in order to evaluate the 
specificity of the method for identification. SNaPaer results agreed with the results of 
polyacrylamide gel (Figure 9) that showed the absence of some amplicons. Several 
SNaPaer markers did not appear in the electropherogram of non-aeruginosa bacteria; 
some cases were consequence of the absence of certain amplicons, others were 
cases of marker specificity to P. aeruginosa. Nevertheless, the presence of unspecific 
peaks in the electropherogram could not be excluded. Therefore, criteria were defined 
in order to achieve an accurate and reliable analysis: peak heights below 50 Relative 
Fluorescence Unit (RFU) were excluded, the lengths of the fragments were carefully 
evaluated and displacements exceeding 1-2 bp from the theoretical position of P. 
aeruginosa peaks were eliminated, and finally, the presence of peaks corresponding to 
unexpected nucleotides were excluded (e.g. a marker suggested as detecting C or T 
could not detect an A). G264, P268, N255, G6, T331 and A491 markers were detected 
in the different Pseudomonas strains, and thus, they were not specific for P. 
aeruginosa. Ac78, N162, A98, M9, G49, Ac7, T205, Ac387 markers were generally 
showed to be specific for P. aeruginosa identification but occasionally could be 
detected in some strains (Table 5); more strains and other Pseudomonas species 
should be tested to clarify the specificity of these peaks. A264, G219, M204, Ac339, 
M36, P100, M228, N288 and T349 were clearly specific markers for identification of P. 
aeruginosa (Figure 10).   
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Table 5. Few SNaPaer markers in non-aeruginosa species.  Black ticks represent the positions with specific 
peak. Blue crosses represent the absence of peak.  
Strains Ac78 N162 A98 M9 G49 Ac7 T205 Ac387 
Pseudomonas aeruginosa         
Pseudomonas fluorescens × × × ×  × × × 
Pseudomonas putida × × × × × × × × 
Pseudomonas savastanoi pv. glycinea × × × × × × × × 
Pseudomonas savastanoi pv. phaseolicola × × × ×  × × × 
Pseudomonas syringae pv. helianthi × × × × × × × × 
Pseudomonas syringae pv. maculicola × × ×  × × × × 
Pseudomonas syringae pv. oryzae × × × × × × × × 
Pseudomonas syringae pv. syringae   × ×     
Pseudomonas syringae pv. tabaci × × × × × × × × 
Pseudomonas syringae pv. tomato × × × × × × × × 
Xanthomonas axonopodis pv. citri × × × × × × × × 
Xanthomonas campestris pv. campestris × × × × × × × × 
Burkholderia cenocepacia 4201 × ×  × ×  × × 
Burkholderia cenocepacia 4219 × ×  × ×  × × 
Burkholderia cenocepacia 4203 × ×  × ×  × × 
Burkholderia cenocepacia 4164 × ×  × ×  × × 
Burkholderia cenocepacia 4178 × ×  × ×  × × 
Burkholderia cenocepacia 4234 × ×  × ×  × × 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Representative SNaPaer assay of Pseudomonas aeruginosa: Blue represents specific markers to 
Pseudomonas aeruginosa. The remaining are non-specific markers to Pseudomonas aeruginosa.  
* Markers occasionally detected in some non-aeruginosa Pseudomonas strains. 
 
 
 
          *  *                         *               *  *                   *                                                *    * 
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4.4. Sampling of clinical Pseudomonas aeruginosa in bronchiectasis 
patients 
P. aeruginosa isolates can be easily collected from the sputa of bronchiectasis 
patients. A total of 29 patients were enrolled on this part of the study: 11 with non-CF 
bronchiectasis and 18 with CF bronchiectasis. Table 6 shows the demographic data, 
medical history and spirometric values of the studied patients. Most patients (60%) 
presented diffuse bronchiectasis according to the HRCT. The remaining 40% 
presented located bronchiectasis on the different lobules (right and left superior, inferior 
or medium) or ligula. Patients with frequent episodes of exacerbation presented higher 
values of C-reactive protein, a response to the frequent inflammation. As predictable, 
the average of FEV1 was lower among older non-CF bronchiectasis patients compared 
to younger patients (1.18 L versus 1.71 L respectively). FEV1 values represent the 
volume of air that can forcibly be blown out in 1 second, after full inspiration. CF and 
non-CF bronchiectasis patients with long term colonisation with P. aeruginosa showed 
lower FEV1 values than patients recently infected or uninfected with this bacterium 
(e.g. average FEV1 values of 0.58 L and 1.86 L were observed respectively for CF 
patients with and without long term colonisation, respectively). The overall average PF 
in non-CF patients with bronchiectasis was 62.8%, while in CF patients was 56.2%. As 
CF patients with bronchiectasis are generally younger compared with non-CF patients, 
they tended to acquire P. aeruginosa chronic colonisation at younger ages (27 versus 
48 year-old respectively). The colonisation of bronchiectasis patients with other 
microorganisms, such as Aspergillus species, Burkholderia cepacia complex, 
Haemophilus inluenza, Staphylococcus aureus and Scedosporium apiospermum, was 
more frequently observed in CF than in non-CF bronchiectasis patients (72% versus 
27%, respectively). Occasionally, microorganisms such as Acinetobacter lwoffii, 
Achromobacter xylo, Klebsiella oxytocaand, Klebsiella ozaenae, Rhizobium radiobacter 
and Stenotrophomonas maltophilia could also be found. Eight (72%) non-CF patients 
and 18 (100%) CF patients received antibiotic therapy, including cephalosporins and 
quinolones antibiotics. 
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Table 6. General characteristics of the patients with bronchiectasis included in the present study. 
 
Non-cystic fibrosis Cystic fibrosis 
Number of patients 11 18 
Age 22-54 28-54 
Gender female/male 12/3 6/12 
Patients with exacerbation caused by 
Pseudomonas aeruginosa 
4 (36%) 0 (0%) 
Forced Expiratory Volume per Second 1 (L) 0.58-2.21 0.93-3.94 
Pulmonary Function 37.2-122% 15.9-100.5% 
Patients with haemoptysis 4 (36%) 0 (0%) 
Pseudomonas aeruginosa colonisation* 11 (100%) 8 (44%) 
Colonisation by other microorganisms  3 (27%) 13 (72%) 
C-reactive protein (mg/L) 0.4-37.3 0.7-3.1 
Sinusitis 4 (36%) 12 (67%) 
Antibiotic therapy 8 (72%) 17 (94%) 
 * Hospital record. 
 
Fifty-three sputum samples from patients with bronchiectasis, 16 from non-CF and 
37 from CF patients, were cultured in Cetrimide Agar at 37 ºC. From the total of 
cultured samples, 14 samples of nine non-CF bronchiectasis patients and 33 
samples of 14 CF bronchiectasis patients presented positive culture in Cetrimide. 
Our Cetrimide culturing results showed discrepancies when compared with the 
results provided by the clinicians. From the 11 non-CF patients, nine presented 
Cetrimide cultured bacteria (82%) in the samples tested in our laboratory; 14 of the 18 
CF patients presented positive culture on Cetrimide agar (78%). Interestingly, few 
isolates grown in Cetrimide Agar were not genotyped later due to MLST 
amplification difficulties. With the appropriate corrections by removing the non-
genotyped colonies, 21 patients (six non-CF and 13 CF) were later confirmed as 
presenting P. aeruginosa in our samples, in contrast with the previous results 
obtained from the hospital record (11 non-CF and eight CF with P. aeruginosa) 
(Table 6). Isolates from CF4, CF8, CF11, CF12 and CF13 patients were included 
in our genotyping studies even with negative result presented by the hospital record 
(Table 7). Cetrimide Agar was also the selective isolation medium for P. aeruginosa in 
hospitals. These divergent results may be justified by the different amount of sputa 
employed for culture by hospital technicians and the amount we tested in our 
procedure. The hospital staff used 5 µL of sputa for a single agar plate, while in the 
lab we cultured around 20 µL of sputa on two plates of Cetrimide Agar. We 
increased the amount of the cultured sputa in order to obtain more colonies of P. 
aeruginosa for further genotyping. Another explanation may come from the ability 
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of other organisms to grow on this medium. For example, some isolates of P. 
putida and P. fluorescens are capable to grow on Cetrimide Agar at 30 to 35°C 
(Wong et al., 2011) and could be incorrectly identified by biochemical or molecular 
methodologies.  
The characterisation of the bacterial colonies grown on Cetrimide Agar is shown in 
Table 7. From the 29 patients, 23 showed positive culture in our samples of Cetrimide 
Agar. Twenty (seven non-CF and 13 CF) patients presented colonies with the smooth 
phenotype and two presented colonies with the rough phenotype. Mucoid bacteria 
were found in four patients (17%). Patients colonised with mucoid P. aeruginosa were 
characterised as presenting low (25%), intermediate (50%) and severe mucoidy (25%) 
(Figure 11). Mucoid isolates were observed in NCF2, NCF3, NCF5 and CF1 patients; 
non-CF patients presented PF values (between 54.8 and 85.0%), while the CF1 patient 
presented a PF value of 25%. The colour of the clinical P. aeruginosa colonies ranged 
from white to brown grey. In two non-CF bronchiectasis patients (NCF3 and NCF5), it 
was observed some phenotypic differences between P. aeruginosa isolates. These 
patients presented three and four phenotypically different isolates, respectively (Table 
7). 
The analysis of consecutive samples collected from some patients (six from non-CF 
and eight from CF) revealed that those patients were chronically colonised with P. 
aeruginosa showing similar phenotypic features. No patients with sporadic colonisation 
by P. aeruginosa were observed. 
 
 
 
 
 
Figure 11. Different production of mucus by Pseudomonas aeruginosa isolates: low (A), intermediate (B) and 
severe mucoidy (C).  
  
 A             B          C 
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Table 7. Phenotypic characteristics of Pseudomonas aeruginosa colonies obtained from sputum 
samples of bronchiectasis patients. 
Patients Phenotypic isolates Type Mucoidy Colour 
Non-cystic fibrosis  
   
NCF1 A Smooth Not applicable Grey white 
NCF2 B Mucoid Low White 
NCF3 C Mucoid Intermediate Brown grey 
 D Rough Not applicable Cream orange 
 E Smooth Not applicable White 
NCF4 F Smooth Not applicable Grey white 
NCF5 G Smooth Not applicable Yellow 
 H Smooth Not applicable Green 
 I Smooth Not applicable Brown grey 
 J Mucoid Intermediate Grey white 
NCF6 K Smooth Not applicable Cream grey 
NCF7 L Smooth Not applicable Yellow 
NCF8 M Rough Not applicable Dark yellow 
NCF9 N Smooth Not applicable White 
     
Cystic fibrosis  
   
CF1 O Mucoid Severe Green 
CF2 P Smooth Not applicable Yellow 
CF3 Q Smooth Not applicable Yellow 
CF4 R Smooth Not applicable Yellow 
CF5 S Smooth Not applicable White 
CF6 T Smooth Not applicable Grey white 
CF7 U Smooth Not applicable Grey white 
CF8 V Smooth Not applicable Cream 
CF9 W Smooth Not applicable Cream 
CF10 X Smooth Not applicable White 
CF11 Y Smooth Not applicable Yellow 
CF12 Z Smooth Not applicable Yellow 
CF13 AA Smooth Not applicable Yellow 
CF14 AB Smooth Not applicable Yellow 
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4.5. Colony PCR 
Three different methodologies were tested in a group of 30 P. aeruginosa isolates 
in order to avoid DNA extraction and turn our genotyping strategy more practical 
and faster to be used in routine by clinical laboratories. MLST amplification was 
tested in all isolates and colony PCR strategies followed by polyacrylamide gel for 
visualisation of the products. Amplification of the genes (positive results) was only 
observed in some bacterial isolates (Figure 13). 
  
 
Figure 13.  Percentage of positive results using three different methods: Colony direct-PCR without 
previous treatment, incubation with Genomiphi and treatment with Proteinase K. 
 
Colony direct-PCR showed low efficiency (20.7%), probably due to the presence of 
several impurities and low amount of DNA. In order to increase the DNA quantity 
obtained from the bacterial colonies, Genomiphi-PCR was tested. Genomiphi-PCR 
showed to achieve a good balance between impurities and DNA quantity, which 
allowed a higher percentage of positive PCR results (63.7%). Finally,  we tested 
Proteinase K-PCR - it uses a serine protease that degrades many proteins in the 
native state. Proteinase K-PCR presented 96.1% of positive results. The remaining 
3.9% comprise rough isolates which failed in the three different methods. DNA 
concentration obtained following the treatment with Proteinase K ranged between 
61 ng/µL and 2286 ng/µL. By testing any of the previous samples, a volume of 1 µL 
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of DNA obtained following Proteinase K treatment (for a final volume of PCR 
reaction of 5 µL) was considered enough to reach excellent results.  
Following MLST amplification in 30 samples with bacterial DNA obtained from the 
three different strategies, SNaPaer was applied to the samples. Complete SNaP 
profiles were observed in 50%, 95% and 100% of positive results for Colony direct-
PCR, Genomiphi-PCR and Proteinase K-PCR, respectively. Occasionally samples 
as C5 and G4 presented good SNaP profiles, but the best results were obtained in 
samples with clear bands in the gel, as it was the case of samples G5 and P1 (see 
Figure 14). Sequencing analysis was also successfully performed in samples 
showing clear bands in the gel.  
 
 
 
 
 
 
 
 
 
Figure 14. Polyacrylamide gel of multilocus sequence typing fragments amplified by colony-PCR. L- Ladder; 1 to 
6 - Different isolates of Pseudomonas aeruginosa amplified following Colony direct-PCR (C), Genomiphi-PCR (G) and 
Proteinase K-PCR (P). 
 
4.6. Genotyping Pseudomonas aeruginosa  
A collection of 207 P. aeruginosa isolates (98 isolates from non-CF bronchiectasis 
patients and 109 from CF bronchiectasis patients) was genotyped with SNaPaer 
assay. SNaP profile analysis revealed that 20 out of the 23 SNPs present in the 
SNaPaer panel were polymorphic. SNaPaer typing revealed 43 SNaP profiles 
among the 207 isolates; nine SNaP profiles were observed in non-CF 
bronchiectasis patients (n=6) and 35 SNaP profiles in CF bronchiectasis patients 
(n=13). Generally, non-CF and CF bronchiectasis patients did not share the SNaP 
profile (Annex 15). Non-CF bronchiectasis patients were predominant colonised by 
isolates with a single SNaP profile (67% of the patients) (Figure 15). On the other 
 C1     C2    C3    C4   C5    C6  G1   G2    G3  G4    G5   G6   P1   P2    P3     P4    P5    P6      L 
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hand, most CF bronchiectasis patients (75%) were colonised by isolates with at 
least two different SNaP profiles. The presence of a single SNaP profile per patient 
was commonly found in various patients, including NCF1, NCF2, NCF5, NCF6, 
CF2 and CF11. From six studied non-CF patients, only NCF4 patient presented 
isolates with multiple SNaP profiles in the clinical sample (three different profiles). 
By other side, six CF patients (CF1, CF3, CF5, CF9, CF10, CF12 and CF13) 
presented isolates with multiple profiles in the clinical samples (two to three 
profiles). There was no evidence for the emergence of a single dominant genotype 
among the complete group of patients. 
Phenotypic characteristics of the colony, such as type, size, mucoidy and colour, 
were compared with the observed SNaP profiles, but no relationships could be 
found. Additionally, we compared the SNaP profiles with the phenotypic features of the 
isolates collected at the same patient. Frequently, the isolates with different 
phenotypes showed different SNaP profile. Occasionally, we observed few strains with 
different phenotype and similar SNaP profile. For example, it was possible to collect 
isolates with four different phenotypes in patient NCF5 (Table 7); these isolates later 
resulted in a single SNaP profile in this patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Distribution of Pseudomonas aeruginosa SNaP profiles in Portuguese non-cystic fibrosis and cystic 
fibrosis bronchiectasis patients. The colours represent distinct patients. The node sizes are proportional to the 
number of isolates with similar SNaP profile. Black arrows show patients who share the same SNaP profile. 
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Vertical analysis of the populations of P. aeruginosa among 15 bronchiectasis 
patients (six non-CF and nine CF), who were sampled at least twice, revealed that 
four out of six non-CF bronchiectasis patients (NCF1, NCF2, NCF5 and NCF6) 
presented the same SNaP profile of P. aeruginosa in consecutive samples. The 
remaining two non-CF bronchiectasis patients (NCF3 and NCF4) presented some 
variants (isolates with microvariation, i.e. difference in one or two markers) of the first 
SNaP profile that was genotyped. In CF bronchiectasis patients, we verified that three 
patients (CF1, CF7 and CF9) presented variants of the first SNaP profile in consecutive 
clinical samples. Therefore, cases of microvariation were observed in isolates 
collected from two non-CF (NCF3 and NCF4) and six CF patients (CF1, CF3, CF5, 
CF10, CF12 and CF13). Generally, microvariation events were responsible for the 
presence of multiple SNaP profiles in the same clinical sample. However, CF3, 
CF5 and CF10 patients were colonised by at least two very distinct strains (Figure 
16 and Table 8). In Figure 16 is possible to observe some microevolution events 
among the isolates collected consecutively from the same patient.  Microevolution 
events could be observed in P. aeruginosa isolates collected from patients 
receiving or not antibiotic therapy.  
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Figure 16. SNaP profiles of the isolates collected from different patients: non-cystic fibrosis 4 (NCF4) (A), cystic 
fibrosis 3 (CF3) (B), cystic fibrosis 9 (CF9) (C) and cystic fibrosis 10 (CF10) (D).  
 
Curiously, patients subjected to aggressive therapies (at least three different 
antibiotics and frequent sessions of antibiotherapy) presented very distinct SNaP 
profiles at the end of the therapy. These events were evident in three CF patients 
(CF3, CF4 and CF6) (Table 8).  
In order to study the cross-transmission of P. aeruginosa among non-CF and CF 
patients, the various SNaP profiles and the dates of isolation were compared. The 
arrows in Figure 15 show some patients (e.g. CF1, CF4 and CF10; NCF4 and CF3; 
CF1 and CF6) that share similar SNaP profiles. Nevertheless, no cross-infection 
could be suspected among those patients as the sputum samples were collected 
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from one month to one year later and the patients were not admitted at the hospital 
in the same date. 
Table 8. Patients with very distinct SNaP profile. 
Clone SNaP profile Date Antibiotics 
CF3-1 AATTGCCCGCGAATTGCGTCTCA Set-09 Azithromicin 
Ciprofloxacin 
Amicacin 
Levofloxacin 
CF3-2 AACTGTCTGTGAATTACATCTCA Mar-10 
CF3-5 AATCGTCTGTGAATTACGTCTCA Jan-12 
    
CF4-1 AGCCGTCTGTCAATTACGTCTCA Nov-09 Azithromicin 
Ciprofloxacin 
Linezolid 
Colistin 
CF4-2 AGATGTCCGTGAACTAGGTCTTG May-10 
CF4-3 AGCTGTCTGTGGATTATGTCTTG Jun-10 
    
CF5-1 AACTGTCTGTGAATTACATCTCG May-11 
Ciprofloxacin 
Doxycycline 
Minocycline 
CF5-2 AACTCTCCGCAAACTGTGTCCCG May-11 
CF5-3 AACTGTCCGCGAACTGTGTCCCG May-11 
    
CF6-1 GACTGTCTGTGAATTACATCTCA Mar-10 
Azithromicin  
Doxycycline 
Cotrimoxazole 
Meropenem 
Ceftazidime  
Flucloxacillin 
CF6-2 AACTGTCCGCAAACCGTGTCCCG Apr-11 
    
CF10-1 AACCGTCTCCAGATTGCGTCTCA Nov-10 Tobramycin 
Colistin 
Ciprofloxacin 
Azithromicin 
CF10-4 AACCGTCCGCGGATTGCGTCTCA Mar-12 
CF10-5 AACCGTCTGTGGATGACGTCTTA Mar-12 
 
In order to determine the number of SNaP profiles exclusive from Portuguese 
population of P. aeruginosa, Portuguese P. aeruginosa SNaP profiles were compared 
with online MLST unique entries of P. aeruginosa (obtained from pubMLST at February 
12, 2013). From the 43 SNaP profiles isolated from Portuguese bronchiectasis 
patients, 38 were exclusive from Portuguese patients and had not been previously 
described at MLST database. A set of 484 online MLST entries of P. aeruginosa 
(obtained from pubMLST at February 12, 2013) from sputa and bronchial lavages of 
CF patients from Australia and The Netherlands, in addition to the group of 207 
Portuguese P. aeruginosa from this study, were also compared (Figure 17). The 
isolates from the three countries were found randomly distributed. It was also possible 
to observe that isolates from Australia, Portugal and The Netherlands share some 
SNaP profiles. Moreover, the temporal distribution (1992-2005 and 2006-2012) of the 
isolates reported in the P. aeruginosa MLST database were also studied, however, no 
sub-groups of isolates could be observed in this analysis (Annex 16). 
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Figure 17. Distribution of Pseudomonas aeruginosa SNaP profiles observed in non-cystic fibrosis and cystic 
fibrosis. Portuguese patients with bronchiectasis and in cystic fibrosis patients from Australia and The Netherlands.  
The node sizes are proportional to the number of isolates with similar SNaP profile.  
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5. Discussion 
 
Pseudomonas is a genus belonging to the family Pseudomonadaceae comprising 
more than 200 species (Euzéby, 2008). The genus was initially defined by Migula in the 
19th century (Migula, 1894), according to the criteria for bacterial taxonomy of this 
period (Cohn, 1872). Thus, the first classification of Pseudomonas species was based 
on the morphology observed between different isolates. Since the discovery of the 
genus Pseudomonas, a large number of species matching Migula's vague description 
were isolated from different environments and were assigned to the genus 
(Palleroni, 2008). Nevertheless, several strains have been re-classified based on 
more recent methodologies involving studies of conserved macromolecules 
(Holmes et al., 1987; Tamaoka et al., 1987; Willems et al., 1989; Anzai et al., 
1997). In the 90s, the sequencing of 16S rRNA gene became a routine approach for 
bacteria identification and classification. As a result, reclassifications of bacteria 
according to 16S rRNA sequence analysis have redefined the taxonomy of many 
bacterial species (Anzai et al., 2000) and some strains were identified as being 
misclassified. Thus, some strains previous classified as Pseudomonas species were 
reclassified into different genus, including Acidovorax (Willems et al., 1990; Willems et 
al., 1992), Burkholderia (Yabuuchi et al., 1992), Ralstonia (Yabuuchi et al., 1995), 
Brevundimonas (Segers et al., 1994) and Stenotrophomonas (Palleroni, 1993). In the 
20s, Anzai analysed the 16S rRNA sequences of 128 Pseudomonas species, half of 
them determined in their laboratory and the rest obtained from public databases (Anzai 
et al., 2000). These isolates of Pseudomonas sensu stricto (type species of the genus 
Pseudomonas by Migula in 1894) were assigned into seven distinct groups: “P. 
syringae group”, P. chlororaphis group”, “P. fluorescens group”, “P. putida group”, “P. 
stutzeri group”, “P. aeruginosa group” and “P. pertucinogena group”. Nowadays, 16S 
rRNA gene is the centre of the bacterial classification. However, it is known that the 
16S rRNA gene is highly conserved which poses the question if this gene is suitable to 
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differentiate very closely related species (Wink et al., 2003; Valverde et al., 2006; Dutta 
and Gachhui, 2007; Rivas et al., 2007). Therefore, other genes have been used to aim 
at a more detailed phylogeny such as recA, atpD, carA, gyrB, rpoB and rpoD, whose 
usefulness for species differentiation has been verified in the genus Pseudomonas 
(Hilario et al., 2004). For instance, the genetic distances calculated from the 
concatenating of gyrB and rpoD could be less erroneous than the whole 16S rRNA 
sequences by presenting higher number of base substitutions outside the variable 
regions (Yamamoto et al., 2000). Another good example is the use of rpoB gene for 
separation of closely related Pseudomonas species, with a phylogenetic resolution 
approximately three times higher than previously shown by the 16S rRNA gene (Ait 
Tayeb et al., 2005).  
 
5.1. Taxonomic power of MLST sequences and identification of 
Pseudomonas species using the SNaPaer assay 
Housekeeping genes are suitable to distinguish species and sub-species of the genus 
Pseudomonas, presenting evolutionary rates higher than those of 16S rRNA gene 
(Hilario et al., 2004). MLSA or MLST approaches have been used to study the 
biodiversity within the Pseudomonas genus. MLSA is useful for phylogenetic and 
population structure analyses of Pseudomonas species in an restrict niche (Frapolli et 
al., 2007), while MLST has been developed for testing the genetic diversity of the 
human opportunistic pathogen P. aeruginosa (Curran et al., 2004; Johnson et al., 2007; 
Khan et al., 2008).  
Phylogenies reconstructed in the present study clearly support the hypothesis that 
the Pseudomonas genus is polyphyletic, i.e. the bacteria have multiple origins and 
thus do not share a common ancestor. The present study showed analyses based 
on 16S rRNA, acsA, aroE, guaA, gyrB, mutL, nuoD, ppsA, rpoB, rpoD and trpE 
sequences that included data from complete genomes of the Pseudomonas 
genus. These data clearly showed that the genus requires redefinition, once 
certain isolates are allocated in different group of species depending on the gene 
that is sequenced. Once again, the 16S rRNA gene revealed insufficient number of 
polymorphisms to distinguish between close related species, with the lowest 
resolution level among the tested genes. The nuoD gene showed similar low 
phylogenetic value, only defining a cluster for P. syringae group. The remaining genes 
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(acsA, aroE, guaA, gyrB, mutL, ppsA, rpoB, rpoD and trpE) presented a good 
phylogenetic resolution for definition of almost five Pseudomonas groups (P. 
stutzeri group, P. aeruginosa group, P. putida group, P. chlororaphis group, and P. 
syringae group), suggested by Anzai et al. (2000). In order to get a better 
resolution, with higher bootstrap values, three different phylogenies with 
concatenated genes were constructed and analysed: concatenated gyrB and rpoD, 
concatenated acsA, aroE, guaA, mutL, ppsA and trpE genes and concatenated of 
the seven MLST genes. Those phylogenies clearly defined several groups 
suggested by Anzai et al. (2000), particularly the P. chlororaphis, P. syringae and 
P. stutzeri. P. aeruginosa group was divided in two clusters distinguishing between 
P. aeruginosa and P. mendocina. P. fulva 12-X and P. putida UW4 are clearly 
outlying strains within the P. putida group. The three phylogenies were very 
similar; MLST phylogeny was very useful for identification and genotyping of P. 
aeruginosa. However, the identification of P. aeruginosa could be optimised by the 
application of molecular methods cheaper than MLST. 
In a previous work, we have standardised the SNaPaer assay for P. aeruginosa 
genotyping revealing a discriminatory power of 0.9993 compared with MLST (Eusebio 
et al., 2013). This method exhibited high reproducibility and used a small amount of 
sample, which may be accurate on testing deteriorated samples and might work as a 
good quality control. Here, we evaluated the ability of SNaPaer assay for P. aeruginosa 
identification. The first step of this assay is the amplification of the MLST genes, where 
the different target markers (SNPs) are located; MLST amplification was only observed 
for P. aeruginosa. Therefore, P. aeruginosa strains could be easily distinguished from 
the other species by a typical banding pattern. The analysis of the 23 SNPs 
demonstrated that nine markers were clearly specific of P. aeruginosa and may be 
easily used for identification of the species, particularly A264, G219, M204, Ac339, 
M36, P100, M228, N288 and T349. The remaining markers may be used for 
genotyping and increase the power of strain discrimination.  
 
5.2. Direct application of SNaPaer in clinical isolates 
Molecular methods have been suggested to improve and complement conventional 
practices. A large amount of these methods involve the extraction of genomic DNA 
from bacteria for diagnosis (Müller et al., 1998) and identification purposes (Niemi et 
al., 2001). Methodologies for genomic DNA extraction take several hours and these 
FCUP 77 
Identification and Genotyping of Pseudomonas aeruginosa in Bronchiectasis 
      
 
 
approaches may include the application of: a) lysozyme and Sodium Dodesyl Sulfate 
(SDS) (Flamm et al., 1984); b) SDS, N-cetyl-N,N,N,-trimethyl ammonium bromide 
(CTAB) and Proteinase K (Wilson, 2001); c) lysozyme, SDS and Proteinase K 
(Neumann et al., 1992); or d)  SDS lysis (Syn and Swarup, 2000). These 
methodologies are very laborious, involving microcentrifugation, incubation, 
precipitation, washing and drying steps. In an attempt to improve the efficiency of  DNA 
extraction as well as to decrease the time spent on the process, various commercial 
extraction kits have been suggested, such as genomicPrep™ Purification Bacteria Mini 
Spin Kit (IllustraTM) and ChargeSwitch® gDNA Mini Bacteria Kit (InvitrogenTM). 
Commercial extraction kits are designed for the purification of high-quality genomic 
DNA from several sources. Biotechnology companies including IllustraTM and 
InvitrogenTM offer specific kits for blood, tissue and cells and bacteria, which are 
validated in several applications. Additionally, these kits reduce DNA shearing during 
purification, resulting in more intact genomic DNA. However, commercial extraction kits 
are still limited to small collections due to the high cost. Thus, it is imperative to 
optimise a method that is able to overcome the limitations of the previous extraction 
methods. 
As reported in previous studies and also confirmed in this study, the pre-procedure of 
the sample (such as pre-incubation with Genomiphi or pre-treatment with Proteinase-K)  
and the DNA-isolation strongly influence the efficiency of the PCR  (Whitehouse and 
Hottel, 2007; Dundas et al., 2008; Queipo-Ortuño et al., 2008; Dauphin et al., 2009). In 
our study, we proposed avoiding the step of DNA extraction from bacteria and 
compared colony direct-PCR without pre-treatment with colony direct-PCR with two 
different pre-treatments: Genomiphi and Proteinase K. The most sensitive molecular 
method was obtained using the colony PCR with Proteinase K pre-treatment. Previous 
studies showed already that Proteinase K pre-treatment allows a more sensitive and 
reliable extraction of bacterial DNA from clinical samples (Deschaght et al., 2009). 
Other advantage of the colony PCR with Proteinase K pre-treatment might be the small 
amount of DNA that is required (60.66 ng/µL of DNA) and the expeditious method. 
Taking into account the cost / benefit ratio, the pre-treatment with Proteinase K was 
applied in P. aeruginosa isolates from bronchiectasis patients for bacterial population 
analysis. The SNaPaer method with Proteinase K pre-treatment may offer P. 
aeruginosa genotypes faster (eight hours) and cheaper (a cost six to seven times less) 
than MLST. 
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5.3. Bronchiectasis patients and Pseudomonas aeruginosa 
colonisation 
Bronchiectasis is a pulmonary disease caused by numerous underlying conditions and 
environmental injuries to the airways. It is well known that CF is a genetic common 
cause of bronchiectasis. Adult CF patients with less severe functional abnormalities are 
often clinically similar to non-CF bronchiectasis patients (Nick and Rodman, 2005).  
The treatment of CF and non-CF bronchiectasis is quite similar, involving chest 
physical therapy and antibiotics. However, there are various reasons why it is 
imperative to distinguish CF and non-CF bronchiectasis patients. For example, even 
though the DNase is indicated as an important component for treatment of CF patients, 
it is contraindicated in non-CF bronchiectasis due to the deterioration of lung function 
that is observed (O'Donnell et al., 1998). Nevertheless, the differences between CF 
patients with less severe functional abnormalities and non-CF bronchiectasis seem to 
be increasingly difficult to recognise. An interestingly example was reported by 
Bienvenu, in 2010. In this study, a group of more than 100 patients with normal sweat 
chloride values and diagnosed with idiopathic bronchiectasis had one or two CFTR 
mutations (Bienvenu et al., 2010). Thus, the appropriate diagnostic of CF patients 
should be accompanied by the screening of CF mutations. A deep evaluation of the 
pathologic situation of each patient is recommended; PF testing and the register of 
associated pathologies have been included in this evaluation. However, on the top of 
the list of risk conditions associated with bronchiectasis is the clinic history of 
severe infection.  
Bacterial infection is a main cause of morbidity in non-CF and CF bronchiectasis 
patients. Given the importance of airway infection in the pathogenesis of 
bronchiectasis, a wide range of studies have been performed to identify and 
characterise bacteria in this niche (Pasteur et al., 2000; Angrill et al., 2002; King et al., 
2006; King et al., 2007). These studies have generally indicated the most common 
pathogens to be H. influenzae and P. aeruginosa, followed by Moraxella catarrhalis, 
Streptococcus pneumonia, Staphylococcus aureus and nontuberculous mycobacteria. 
Although the pathophysiologic mechanisms are similar in non-CF and CF 
bronchiectasis patients, the bacterial species that colonise both groups of patients may 
differ. According to our findings, the bronchiectasis patients were colonised with 
potential pathogenic organisms and P. aeruginosa was the most frequently isolated 
microorganism. However, when we compared our P. aeruginosa identification results 
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with hospital record, we verified discrepancies. These differences seem to be related 
with the different amount of sputa employed for culture and the identification method 
used. We used Cetrimide Agar culture combined with SNaPaer assay for identification 
of typical P. aeruginosa. By other side, hospital laboratory used a conventional method, 
culture of P. aeruginosa in Cetrimide Agar, and biochemical tests for identification. The 
disadvantages of the use of Cetrimide Agar for P. aeruginosa identification, such as the 
ability of other organisms to grow on this medium at 30 to 35°C, have been 
previously described (Wong et al., 2011). Additionally, King has also described that 
30–40% of sputum samples may fail to grow bacteria in conventional culture (King, 
2009). Therefore, previous studies may underestimate the extent of microbial diversity 
within the pulmonary tree and particularly fail the detection of P. aeruginosa in the 
lungs of the patients. Thus, it is necessary the implementation of easy-doing and cheap 
molecular methods in hospitals to improve P. aeruginosa detection and identification. 
Several molecular methods have been described to the diagnosis P. aeruginosa. 
These methods have been employing several targets including 16S 
rRNA, algD, oprI, oprL, toxA, gyrB, and ecfX genes (Karpati and Jonasson, 1996; De 
Vos et al., 1997; Qin et al., 2003; da Silva Filho et al., 2004; Lavenir et al., 2007; 
Motoshima et al., 2007; Anuj et al., 2009). False-positive results were reported with 
genes algD, toxA, 16S rRNA and oprI based methods (Lavenir et al., 2007; Anuj et al., 
2009); therefore, gyrB and ecfX genes have been suggested as more suitable targets 
to the diagnosis P. aeruginosa (Lavenir et al., 2007; Anuj et al., 2009; Tang et al., 
2013). Quantitative PCR (Cattoir et al., 2010)  and magnetic enrichment and separation 
(Tang et al., 2013) have been suggested by testing this two genes (gyrB and ecfX) for 
P. aeruginosa molecular diagnosis. Quantitative PCR may become difficult in some 
samples by the presence of PCR inhibitors, occasional cross-reaction and, sometimes, 
low detection limit. Magnetic methods are very expensive and therefore applied to 
small collections. 
SNaPaer is an easy-doing and cheap molecular assay that may be complementary to 
culture methods for identification of P. aeruginosa. However, we verified that SNaPaer 
may miss the identification of some atypical P. aeruginosa strains database. The two 
strains (PAO1 and PA7) collected from NCBI represent atypical strains of P. 
aeruginosa that could not be fully characterised by SNaPaer. The application of 
SNaPaer for identification of P. aeruginosa in the samples collected from 
bronchiectasis (non-CF and CF) patients here studied, revealed that around 66% of 
patients have been colonised with this species. From those approximately 30% have 
been reported as presenting exacerbation episodes due to this bacteria (Nicotra et al., 
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1995a). However, we did not find an association between P. aeruginosa colonisation 
and exacerbation episodes. P. aeruginosa strains may differ greatly in growth, 
morphology or pigmenting production (Bragonzi et al., 2009; Winstanley et al., 2009). 
These changes in the abundance of some isolates with a particular phenotype cannot 
be justified by simple antibiotic selection (Fothergill et al., 2010). However, we cannot 
exclude the possibility that the antibiotics administered to the patient may affect the 
genes expressed in P. aeruginosa. A large part of the phenotypic changes do not alter 
the global ﬁngerprint of the bacterial genome; perhaps because only a few loci are 
affected (Breitenstein et al., 1997). As a consequence, several isolates of P. 
aeruginosa with identical morphology may have different SNaP profiles (Ernst et al., 
2003). More rarely, distinct phenotypic strains may have the same SNaP profile, as 
shown in the results section. Another consequence of antibiotic administration against 
P. aeruginosa is the possible rise of non-aeruginosa microorganisms. Those have been 
more frequently observed in the lungs of patients receiving antibiotics for treatment or 
eradication of P. aeruginosa, namely ciprofloxacin, levofloxacin, colistin and 
tobramycin. Thus, despite the changes in the lungs caused by the disease, other 
factors such as antibiotics and microbial competitors may determine what 
microorganisms are able to infect each group of bronchiectasis patients (non-CF and 
CF). 
 
5.4. Pseudomonas aeruginosa genetic diversity in patients with 
bronchiectasis 
In the last decades, P. aeruginosa populations with different structures have been 
described. Several studies suggest that P aeruginosa present an epidemic and 
panmictic population structure, where the different clones are randomly distributed 
(with no sub-population formation) and successful clones can be rapidly broken up by 
recombination (Ripp et al., 1994; Pirnay et al., 2002; Lee et al., 2006). Lomholt et al. 
described an epidemic structure, in which a successful clone may increase and 
dominate for a time, and then disappear as a result of recombination (Lomholt et al., 
2001). The combination of sequencing of three outer membrane lipoprotein gene, a 
DNA-based fingerprint, serotype and pyoverdine type of clinical and environmental P. 
aeruginosa isolates revealed genetic mosaicism (Pirnay et al., 2002). A later study 
performed by Curran et al. and using MLST scheme suggested an epidemic population 
structure punctuated by closely related genotypes or clonal complexes (Curran et al., 
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2004). In 2007, a study that analysed the conserved core and flexible accessory 
genome of 240 P. aeruginosa strains indicated that the population structure was more 
complex than previously reported, with the presence of a clonal structure (Wiehlmann 
et al., 2007). A study of P. aeruginosa structure combining clinical and environmental 
isolates described a non-clonal epidemic structure, i.e. without predomination of few 
successful clones and no widespread CF clones (Pirnay et al., 2009). More recently, a 
study of  P. aeruginosa clinical and environmental isolates from both sides of the 
Mediterranean basin supported the previous hypothesis of a panmictic population 
structure punctuated by epidemic clones (Maatallah et al., 2011). 
Here, we have verified that the clinical population of P. aeruginosa isolates is epidemic. 
When we analysed the sub-populations of P. aeruginosa from different bronchiectasis 
patients, we verified patient specific sub-populations. This implies that a large part of 
the clones are specific, which is in agreement with previous findings (van Mansfeld et 
al., 2010). However, a limited overlap between isolates from non-CF and CF 
bronchiectasis patients rejects the hypothesis of a occasionally non-random distribution 
of isolates consisting on a population of isolates originating from both CF and non-CF 
patients (Lanotte et al., 2004). This result is probably due to the higher discriminatory 
power of SNaPaer when compared with RAPD, used by Lanotte et al. (Waters et al., 
2012). In order to obtain a global view of P. aeruginosa strains from bronchiectasis 
patients worldwide, we also compared the SNaP profiles of Portuguese P. aeruginosa 
isolates collected from bronchiectasis patients with CF patients from pubMLST 
observed in distinct countries (Australia and The Netherlands). We verified that the 
Portuguese isolates shared some SNaP profiles with patients from other countries and 
presented an epidemic population structure, which is consistent with previous results 
(Pirnay et al., 2002; Pirnay et al., 2009; Eusebio et al., 2013).  
Portuguese bronchiectasis patients (non-CF and CF) seem to be colonised by their 
own specific strains. However, some patients seem to be colonised simultaneously with 
multiple strains, particularly in CF bronchiectasis patients. If the various alternative 
strains present a different susceptibility to antibiotic therapy, this observation may have 
important implications on the controlling of exacerbations. In the standard practice in 
clinical microbiology laboratories, a single colony is used for identification of species. In 
fact, this practice will not dependably yield the essential information to drive 
antimicrobial therapy in bronchiectasis patients, especially in CF patients where the 
percentage of simultaneously colonisation by multiple strains are common Murphy et 
al. reported that one potential mechanism for the failure of antibiotic therapy in patients 
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with H. influenzae is the presence of multiple strains with different antimicrobial 
susceptibilities (Murphy et al., 1999). In this context, clinicians should consider all 
different strains and their antibiotic susceptibilities for the application of a directed 
antibiotic therapy. Another assumption on this study was that few patients were found 
consecutively colonised with P. aeruginosa isolates with similar or closely related SNaP 
profiles, which seems to be a consequence of microevolution events (van Mansfeld et 
al., 2010; Eusebio et al., 2013). These events are well-known in patients with chronic 
colonisation with P. aeruginosa (Bragonzi et al., 2009; Cramer et al., 2011; Hogardt 
and Heesemann, 2013) and support the previously described plasticity of P. 
aeruginosa genome to accumulate alterations and adapt to a stressful pulmonary 
environment (Folkesson et al., 2012). During chronic colonisation, P. aeruginosa 
suffers changing pressures exerted by the host environment: diverse nutrient 
availability, challenges of the immune defences, antimicrobial therapy, and oxidative 
and nitrosative stress. Thereby, P. aeruginosa must survive and adapt to the high 
stressful conditions that have a big impact on its subsequent evolution. Moreover, the 
competition with other microorganisms and the osmotic stress resulting from the high 
viscosity of the mucus also influence the adaptation (Folkesson et al., 2012).  
Bronchiectasis patients generally presented a stable disease punctuated by 
exacerbation episodes. During these episodes, the symptoms of the disease become 
more pronounce and patients usually resort to clinicians. Exacerbation episodes are 
usually controlled by the administration of large spectrum antibiotics (such as 
ciprofloxacin and levofloxacin) to the patients. Furthermore, P. aeruginosa is usually a 
species that require special attention from the clinicians. Once acquired, chronic P. 
aeruginosa infection cannot be eradicated, which combined with the poor diagnostic 
makes this bacterium so common in bronchiectasis patients. Isolates collected from 
periods of clinical stability or from stable and exacerbation periods revealed the 
presence of the same isolates in the various phases (Aaron et al., 2004; Tunney et al., 
2013). We observed similar results in Portuguese non-CF and CF bronchiectasis 
patients, which suggests that changes in lung P. aeruginosa population do not 
account for exacerbations in patients with bronchiectasis. We also compared the 
strains of the different patients and verified that most patients presented specific strains 
with unique SNaP profiles, which rejects the hypothesis that cross-infection may be 
common among these patients, as previously suggested (Dwivedi et al., 2009). The 
absence of cross-infection is due to hygiene protocols, evolving contact barrier 
precautions for medical and nursing staff caring for patients colonised or infected with 
microorganisms. However, when these precautions and others are not taken, cross-
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transmission or cross-infection occurs. Several routes of P. aeruginosa colonisation 
can be distinguished (Boyer et al., 2011). Bronchiectasis patients may become 
colonised during their periodical medical appointments, a route that depends of the 
number of other patients already colonised. By other side, transmission of 
microorganisms from one patient’s body section to another is also frequently. 
Additionally, in several patients, bacteria develop antibiotic resistance, by new specific 
mutations or horizontal transfer of antibiotical resistance genes, such as mexA and 
mexB (Poole, 2004). These endogenous acquisitions usually occur under antibiotic 
pressure and may be very problematic for patient’s treatment. The administration of 
antibiotics has positive results only when correctly applied. The administration of 
intravenously or topically antibiotics may serve as a way to reduce or completely 
eradicate the susceptible bacteria, thereby avoiding the development of resistance. In 
other hand, the excessive use of antibiotics may increase the selection pressure 
thereby increasing the number of resistant strains. Thus, several infection control 
strategies may be considered to reduce the prevalence of colonisation and prevent the 
emergence of resistant strains. Barrier precautions are imperative for infection 
prevention in the hospitals, which includes placing a patient in a single-bed room, hand 
disinfection and clinicians should approach the patient only when wearing gloves and 
gowns. However, barrier precautions alone have often been insufficient to prevent the 
resistant strains. Thereby, additional precautions are needed to be taken. The 
complete eradication of bacteria may be very effective in the control of the rise of new 
resistant strains. Recently, the administration of non-absorbable antibiotics applied into 
the intestinal tract has aroused particular interest among clinicians (Saene et al., 2003). 
The combination of the previous treatment with oropharyngeal decontamination and a 
short course of intravenous antibiotic prophylaxis have revealed a reduced incidence of 
respiratory tract infections in treated patients. The combination of all those precautions 
will allow the improvement of bronchiectasis patients and thereby their quality of life.  
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6. Conclusions 
 
SNaPaer assay represents a practical, reproducible, and sensitive alternative to MLST 
that allows P. aeruginosa genotyping in a single amplification and mini-sequencing 
reactions. Furthermore, SNaPaer seems to be very useful for identification of P. 
aeruginosa strains with the exception of atypical strains, such as PAO1 and PA7. 
Here, we also selected a new pre-treatment with Proteinase K for maximising the 
performance of SNaPaer in routine work of clinical laboratories. The Proteinase K-PCR 
followed by the SNaPaer assay allowed the exclusion of DNA extraction step, saving 
time and money. Thus, in a few hours it was possible to obtain reliable results of 
identification and genotyping of P. aeruginosa strains. 
SNaPaer together with Proteinase K-PCR was successfully employed to a population 
of 207 P. aeruginosa isolates. The clinical population of P. aeruginosa was highly 
diverse and characterised by high-level of host-specificity. Microevolution events were 
the most common mechanism of evolution in P. aeruginosa strains from bronchiectasis 
patients. However, some patients seem to be colonised simultaneously with multiple 
strains, particularly in CF bronchiectasis patients. Patients submitted to aggressive 
antibiotic therapies presented at the end of the therapy P. aeruginosa with SNaP 
profiles very distinct from the SNaP profile of first isolate. 
Cross-transmission and cross-infection by P. aeruginosa were not found among 
different non-CF and CF bronchiectasis patients. In general, each patient presented 
specific strains with unique SNaP profiles. The absence of cross-infection can be due 
to hygiene protocols applied in the hospital. 
 
FCUP 85 
Identification and Genotyping of Pseudomonas aeruginosa in Bronchiectasis 
      
 
 
 
 
 
7. Future Prospects  
 
During this work, we verified that SNaPaer is very promising to the identification and 
genotyping of P. aeruginosa. However, in order to enlarge the ability of SNaPaer for 
identification and genotyping of other species in the Pseudomonas genus, particularly 
in species closely related to P. aeruginosa, it is imperative that more genomic data be 
available. As sequencing is being performed actively and at a fast-paced rhythm, we 
believe that in a near future, thousands of sequences will be available for non-
aeruginosa species.  
In bronchiectasis patients, it is very problematic to study and compare the evolution of 
bacterial populations. The complex treatment and care offered to the patients, 
particularly when they are admitted at distinct hospitals, and the heterogenic microbial 
populations which may infect those patients are some of the problems that researchers 
face on clinical studies.  However, standard molecular methodologies, such as 
SNaPaer assay, may improve such knowledge of the evolution and population 
structure of P. aeruginosa in bronchiectasis patients. Studies have provided imperative 
information for correct and directed therapies, which may improve the quality of life of 
these patients.  
The study of uncultivated P. aeruginosa and evolution in bronchiectasis patients still 
remains an interesting area. The study of these strains may be a source of diversity 
incredibly important for understanding the exacerbation episodes. The identification of 
biomarkers for identification of chronic infections at early stage remains a critical area 
still needing intensive research. Such studies facilitate the prevention of bacterial 
infections and can be very helpful to control the development of bronchiectasis 
disease. 
FCUP 86 
Identification and Genotyping of Pseudomonas aeruginosa in Bronchiectasis 
      
 
 
With the advances of molecular technology and particularly with next-generation 
sequencing (Schuster, 2008), it is becoming progressively cheap to determine the 
complete genome sequence of bacterial isolates. The comparison of multiple genomes 
of P. aeruginosa strains from airways of bronchiectasis patients will allow obtaining a 
good picture of the bacterial pangenome in patients’ lungs. This picture will expose the 
specific blocks of genes responsible for P. aeruginosa adaptation in this harsh 
environment. 
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Annex 1. Random number for Pseudomonas aeruginosa isolates selection. 
Random number Hour Day 
24  7  5 19  2  4 31 28 21:00:00 28-11-2012 
5 26 28 23  8 24  2  4 21:00:01 28-11-2012 
3 19 16 36 10  7 17 31 21:00:02 28-11-2012 
29 38  3 21 31 27 12  5 21:00:03 28-11-2012 
23 19 26 17  4 24 21 18 21:00:04 28-11-2012 
19 31 30  2 36 32 28 11 21:00:05 28-11-2012 
36 20  1  5 32 30 13 27 21:00:06 28-11-2012 
23 21 19 35 26 29 36 38 21:00:07 28-11-2012 
2 31  5 16 26 27 33 19 21:00:08 28-11-2012 
9  4 19 10  7 23 21 16 21:00:09 28-11-2012 
12 21  1 38 33  5  9 34 21:00:10 28-11-2012 
31 34 27 24  5  4 33 14 21:00:11 28-11-2012 
29 35 24 36  4 33 11 20 21:00:12 28-11-2012 
25 35 30 16 29 36 28 24 21:00:13 28-11-2012 
19 17 14 37 18 23 25 27 21:00:14 28-11-2012 
24 10 28  3  7  9 16 32 21:00:15 28-11-2012 
18 28 14 16 26 21 29 19 21:00:16 28-11-2012 
24 28 35 19  9  8 21 17 21:00:17 28-11-2012 
10 18 27 12  9 29 11  7 21:00:18 28-11-2012 
2 38 10 11  9 15  1  6 21:00:19 28-11-2012 
10  6 35 21  7  9 11 23 21:00:20 28-11-2012 
17 26 23 32  3 29 21  2 21:00:21 28-11-2012 
19  7 17  6 36 33 31 25 21:00:22 28-11-2012 
29 34 32 33 23 28 22 11 21:00:23 28-11-2012 
19 12  9  2 13 14 28 18 21:00:24 28-11-2012 
18  6 26 20  8 27  4 24 21:00:25 28-11-2012 
1 32 25 16 34 20  6  2 21:00:26 28-11-2012 
37 19 29 26 11 17 14  1 21:00:27 28-11-2012 
23 33 19 31 18 24  7 20 21:00:28 28-11-2012 
28 29 15 18 26 16 21 24 21:00:29 28-11-2012 
4 19 31 36 34 33 20 14 21:00:30 28-11-2012 
31 33 13 14  2 34 18 20 21:00:31 28-11-2012 
18 28  4 29 16 24 15 21 21:00:32 28-11-2012 
25 26  4 21  6  7  1 30 21:00:33 28-11-2012 
7 19  1  4 38  6 30  9 21:00:34 28-11-2012 
24 15 35  3 13 33 34  4 21:00:35 28-11-2012 
8  6 34 27  5 10 33 17 21:00:36 28-11-2012 
18 36 26 15 34 33  5 25 21:00:37 28-11-2012 
FCUP 112 
Identification and Genotyping of Pseudomonas aeruginosa in Bronchiectasis 
      
 
 
 
Annex 2. Phylogenetic tree of 50 Pseudomonas species based on 16S rRNA gene. The tree was constructed using 
the neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 
replicates. The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; 
purple - Pseudomonas aeruginosa group; red - Pseudomonas putida group; green - Pseudomonas chlororaphis group; 
pink - Pseudomonas syringae group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 3. Phylogenetic tree of 50 Pseudomonas species based on rpoB gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values of 500 replicates. 
The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; purple - 
Pseudomonas aeruginosa group; red - Pseudomonas putida group; pink - Pseudomonas syringae group; green - 
Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 4. Phylogenetic tree of 50 Pseudomonas species based on concatenated rpoD and gyrB genes. The tree 
was constructed using the neighbourjoining method. The number shown next to each node indicates the percentage 
bootstrap values for/from 500 replicates. The colours represent the different groups defined by Anzai (2000): purple - 
Pseudomonas aeruginosa group; brown - Pseudomonas stutzeri group; red - Pseudomonas putida group; pink - 
Pseudomonas syringae group; green - Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. 
Pseudomonas protogens Pf-5 and Pseudomonas brassicacearum NFM421 are two strains that do not belong to any 
previously defined group; Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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 Annex 5. Phylogenetic tree of 50 Pseudomonas species based on acsA gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 replicates. 
The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; red - 
Pseudomonas putida group; pink - Pseudomonas syringae group; purple - Pseudomonas aeruginosa group; green - 
Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 6. Phylogenetic tree of 50 Pseudomonas species based on aroE gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values of 500 replicates. 
The colours represent the different groups defined by Anzai (2000): purple - Pseudomonas aeruginosa group; brown - 
Pseudomonas stutzeri group; red - Pseudomonas putida group; pink - Pseudomonas syringae group; green - 
Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 7. Phylogenetic tree of 50 Pseudomonas species based on guaA gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 replicates. 
The colours represent the different groups defined by Anzai (2000): purple - Pseudomonas aeruginosa group; brown - 
Pseudomonas stutzeri group; red - Pseudomonas putida group; pink - Pseudomonas syringae group; green - 
Pseudomonas chlororaphis group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 8. Phylogenetic tree of 50 Pseudomonas species based on mutL gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 replicates. 
The colours represent the different groups defined by Anzai (2000): pink - Pseudomonas syringae group; green - 
Pseudomonas chlororaphis group; blue - Pseudomonas fluorescens group; brown - Pseudomonas stutzeri group; red - 
Pseudomonas putida group; and purple - Pseudomonas aeruginosa group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 9. Phylogenetic tree of 45 Pseudomonas species based on nuoD gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 replicates. 
The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; purple - 
Pseudomonas aeruginosa group; red - Pseudomonas putida group; green - Pseudomonas chlororaphis group; pink - 
Pseudomonas syringae group; and blue - Pseudomonas fluorescens group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex  10. Phylogenetic tree of 50 Pseudomonas species based on ppsA gene. The tree was constructed using 
the neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 
replicates. The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; 
red - Pseudomonas putida group; purple - Pseudomonas aeruginosa group; pink - Pseudomonas syringae group; blue - 
Pseudomonas fluorescens group; and green - Pseudomonas chlororaphis group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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Annex 11. Phylogenetic tree of 50 Pseudomonas species based on trpE gene. The tree was constructed using the 
neighbourjoining method. The number next to each node indicates the percentage bootstrap values for 500 replicates. 
The colours represent the different groups defined by Anzai (2000): brown - Pseudomonas stutzeri group; green - 
Pseudomonas chlororaphis group; pink - Pseudomonas syringae group; blue - Pseudomonas fluorescens group; red - 
Pseudomonas putida group; and purple - Pseudomonas aeruginosa group. Pseudomonas protogens Pf-5 and 
Pseudomonas brassicacearum NFM421 are two strains that do not belong to any previously defined group; 
Chromohalobacter salexigens DSM 3043 was used as an out-group. 
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 Annex 12. Phylogenetic tree of 50 Pseudomonas species based on concatenated acsA, aroE, guaA, mutL, 
ppsA and trpE genes. The tree was constructed using the neighbourjoining method. The number next to each node 
indicates the percentage bootstrap values for 500 replicates. The colours represent the different groups defined by 
Anzai (2000): brown - Pseudomonas stutzeri group; purple - Pseudomonas aeruginosa group; red - Pseudomonas 
putida group; green - Pseudomonas chlororaphis group; blue - Pseudomonas fluorescens group; and pink - 
Pseudomonas syringae group. Pseudomonas protogens Pf-5 and Pseudomonas brassicacearum NFM421 are two 
strains that do not belong to any previously defined group; Chromohalobacter salexigens DSM 3043 was used as an 
out-group. 
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Annex 13. Pseudomonas aeruginosa that showed multilocus sequence typing gene amplification problems.  
Black crosses represent no amplification of the specific gene. Red, orange and green ticks represent genes 
amplified with an annealing temperature of 50ºC, 52ºC and 54ºC, respectively.  
Strains aroE acsA guaA nuoD mutL ppsA trpE 
Pseudomonas aeruginosa ATCC 33358        
Pseudomonas aeruginosa PAO1       
Pseudomonas aeruginosa PA1*       
Pseudomonas aeruginosa PA2*       
Pseudomonas aeruginosa PA3*       
Pseudomonas aeruginosa PA4*       
Pseudomonas aeruginosa PA5*       
Pseudomonas aeruginosa PA6*       
Pseudomonas aeruginosa PA7*       
Pseudomonas aeruginosa PA8*       
Pseudomonas aeruginosa PA9*       
Pseudomonas aeruginosa PA10*       
Pseudomonas aeruginosa PA11*       
*Clinical isolates. 
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Annex 15. Distribution of Pseudomonas aeruginosa isolates of bronchiectasis patients. The different colours 
represent distinct p non-cystic fibrosis (non- CF) and cystic fibrosis (CF) patients.  The node sizes are proportional to the 
number of similar SNaP profiles. 
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Annex 16. Phylogenetic network of Pseudomonas aeruginosa isolates (data obtained from MLST website in 
addition to our Portuguese collection). MLST profiles from the online database (http://pubmlst.org/paeruginosa/) 
were converted into SNaP profiles in order to design the network. The colours represent the period during which the 
collection of the isolates was carried out. 
 
